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ABSTRACT 
 
NICOLE M. RAMOCKI:  IRS-1 and SOCS2 are key regulators of  insulin-like growth 
factor signaling in intestinal cancer  
 (Under the direction of Dr. P. Kay Lund) 
 
 The growth hormone/insulin-like growth factor (GH/IGF) axis has been implicated at 
various stages of tumor progression in colon cancer.  Insulin receptor substrate-1 (IRS-1) is a 
major downstream signaling molecule of insulin, IGF-I, and IGF-II and is constitutively 
active in various tumor types, including breast.  Its role in colon cancer has not been studied 
in vivo to date.  Conversely, Suppressor of Cytokine Signaling-2 (SOCS2) has been shown to 
limit this pathway and could thereby limit tumorigenesis in intestine.  IRS-1 and SOCS2 
deficient mice were crossbred with the ApcMin/+ model of intestinal polyposis to test whether 
IRS-1 or SOCS2 play a role in tumor formation in intestine.  SOCS2 deficient mice were 
crossbred with GH-transgenic mice to test the hypothesis that SOCS2 normally limits GH-
mediated trophic and tumorigenic actions.  In mice with partial and absolute IRS-1 
deficiency, intestinal crypt apoptosis levels were significantly increased, most notably in the 
putative stem cell region.  Partial and absolute IRS-1 deficiency also lead to decreased tumor 
formation and decreased expression of a putative stem cell marker and β-catenin 
transcriptional target, Sox9, in intestine of ApcMin/+ mice.  Partial SOCS2 deficiency in GH-
transgenic mice lead to greater intestinal growth.  SOCS2 deficiency lead to greater 
tumorigenesis in intestine of GH-transgenic and ApcMin/+ mice, but not using the AOM/DSS 
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model of inflammation-associated colon cancer.  Overall, these studies suggest that IRS-1 
plays a significant role in intestinal tumorigenesis and SOCS2 may serve as a crucial tumor 
suppressor by limiting the actions of the GH/IGF-I and IRS-1 pathway.  Future studies will 
be aimed at determining if IRS-1, Sox9, and SOCS2 levels in human intestine can serve as 
useful biomarkers of colon cancer or adenoma risk.   
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A.  Structure of the normal intestine 
  
The wall of the gastrointestinal tract consists of an epithelial cell layer closest to the 
lumen, the laminal propria, a submucosa comprised of fibroblasts, a layer of smooth muscle 
cells making up the muscularis mucosa, circular and longitudinal muscle layers, and the 
external serosa as shown in Figure 1.1a (132).  The enteric nervous system of the gut is 
composed of the myenteric plexus (between the circular and longitudinal muscle layers) and 
the submucosal plexus (beneath the mucosal layer).  The neurons within the plexi regulate 
smooth muscle motility and epithelial cells function (64).  The smooth muscle cells that 
comprise the circular and longitudinal muscle layers are connected by gap junctions, 
allowing electrical current to spread from one cell to adjacent cells in both directions (64).  
The result is a coordinated contraction of the bowel wall that propels luminal contents 
through the digestive tract.  The GI tract is richly perfused by the splanchnic circulation, 
which takes up nutrients and delivers nutrients, oxygen, and regulatory hormones to the gut 
(64).   
The common bile/pancreatic duct enters the intestine at the duodenum and delivers 
digestive enzymes from the pancreas and bile from the liver, which are critical for digestion 
of carbohydrates, protein, and lipids (64).  The epithelial layer secretes ions, mucus, and 
water, and produces brush border enzymes and transport proteins crucial for the breakdown 
and absorption of food.  The epithelial layer also serves as a barrier, preventing bacteria and 
ingested toxins from entering the body.  Immune cells within the bowel wall protect against 
toxins or infection by pathogenic bacteria in the gut.  The lamina propria is composed of 
mesenchymal cells (fibroblasts and myofibroblasts), capillaries, immune cells, and smooth 
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muscle cells (132).  Fibroblasts also reside in the muscularis mucosa, along with a collagen-
rich extracellular matrix (132).  The epithelial layer receives many of its proliferative and 
developmental signals from the underlying mesenchymal cells (106, 132, 139, 167).    
 
B.  The intestinal epithelium and intestinal adaptation   
 
As shown in Figure 1.1b, the intestinal epithelium is made of a crypt-villus axis in the 
small intestine and a crypt-surface epithelium axis in the colon.  Villi, which are finger-like 
luminal projections that start at the top of the crypts, greatly increase the surface area in the 
small intestine and allow more efficient nutrient digestion and absorption (109).  The 
mammalian intestinal epithelium continuously renews itself every 3-5 days (84).  Cells are 
born near the base of the crypt, where the stem cells and progenitor cells reside.  Crypt cells 
migrate up to the villus where they differentiate into either an enterocyte, enteroendocrine, or 
goblet cell phenotype.  Once cells reach the tip of the villus, they are sloughed off in a 
process called anoikis.  In small intestine, a subset of cells migrate downward to the very 
base of the crypt to become Paneth cells, which are thought to function in innate immunity 
by secreting microbicidal peptides (33).  Within the crypts a small but significant number of 
cells undergo spontaneous apoptosis (109).  In order for the functional mass of the intestinal 
epithelium to remain constant, the rate of cell loss by anoikis and spontaneous apoptosis must 
closely match the rate of production of new cells by proliferation of stem cells and progenitor 
cells.   
Maintenance of the functional mass of the epithelium is necessary for the epithelial 
layer to maintain its secretory, absorptive, and barrier functions.  However, the intestine has a 
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remarkable ability to alter the rate of renewal and mass of intestinal epithelium to match 
physiological or pathophysiological challenge, a process termed intestinal adaptation.  
During oral nutrient restriction, the intestinal crypts reduce their rate of proliferation and 
increase apoptosis resulting in a decrease in mass of the epithelium (32, 46).  This is an 
appropriate physiological response to the reduced need for digestion and absorption of 
enteral nutritients.  Loss of intestinal mass due to injury, disease, or resection results in 
compensatory crypt and villus hyperplasia in remnant intestine that can maintain the 
intestine’s digestive and absorptive functions despite its loss in length (36, 103).  This occurs 
by increased crypt proliferation, increased crypt fission, and ultimately an increase in 
circumference of remnant intestine (36).  The insulin-like growth factor (IGF) system has 
been shown to be a major mediator of normal and adaptive growth of the intestine (31, 55, 
90, 103, 120, 137).  Mice expressing an IGF-I transgene have increased intestinal mass, 
associated with increased villus height, crypt depth, and cell mitosis (137).  IGF-I treatment 
in rats and smooth muscle-specific IGF-I transgenic expression in mice increase mucosal 
hyperplasia following small bowel resection (31, 90). 
 
C.  Crypt stem and progenitor cells 
 
Based on stem cell characteristics in other organs such as the nervous system, it is 
generally believed that stem cells show slow, but long-lasting rates of cell division to give 
rise to shorter lived and faster cycling progenitor cells.  True stem and progenitor cells should 
also be multipotent, having the ability to differentiate into all epithelial lineages (11, 27).  At 
present, there is no fully defined or validated biomarker of intestinal stem cells.  Current 
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theories indicate that a small population of multipotent stem cells reside in the crypts, which 
divide slowly and asymmetrically to renew the stem cell and produce a daughter progenitor 
cell (155).  In asymmetric division, stem cells undergo selective segregation of their DNA 
strands during mitosis, with the mother strands retained in the stem cells while the daughter 
strands are donated to the newly-generated progenitor cell (155).  This scenario makes 
teleological sense, since random DNA mutations from cell division would less likely be 
introduced in the conserved DNA strands in the stem cells (155).  This contention is based on 
label-retention studies, which involve administration of multiple, high doses of 3[H] 
thymidine or BrdU to label slowly dividing (as well as rapidly dividing) cells (27).  A period 
of ‘washout’ spanning several weeks is then allowed so the label is diluted and undetectable 
in rapidly dividing cells, but is retained in long-lived and asymmetrically dividing stem cells, 
or ‘label retaining cells’ (LRCs) (87).  Thus the LRCs retain 3[H] thymidine or BrdU due to 
labeling of the ‘mother DNA’ and retention of this DNA in the LRC or stem cell.  Early 
studies using autoradiography showed slow-cycling cells could be labeled radioactively, and 
this method could be used to identify cells that give rise to all cell types within the crypt 
epithelium (27).  While this type of asymmetrical cell division would likely occur during 
homeostatic conditions, it has been proposed that stem cells can divide symmetrically into 
two stem cells during adaptive growth and into two daughter cells during atrophy or nutrient 
restriction (109).  Through use of label retention and radiation to speed cellular turnover, 
Potten postulated that the crypt stem cells reside around positions 4-6 (151, 155), a claim that 
is still controversial.   
Progenitor cells derived from crypt stem cells can be termed ‘transit cells.’  This is 
because these cells show rapid, but limited, cell division and migrate up to the villus or to the 
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crypt base, where they differentiate into the four terminally differentiated lineages.  A major 
question in intestinal epithelial biology is the molecular and functional phenotype of crypt 
stem and progenitor cells.  Many candidate stem cell markers have been proposed.  Musashi 
and CD133 have been proposed as stem cell markers, but these biomarkers appear to label 
crypt stem and progenitor cells, and cells expressing these biomarkers have not been shown 
to be multipotent (7, 133, 136, 154).  Recent data show that Lgr5, a G-protein coupled 
receptor with no known ligand, may represent a biomarker of multipotent crypt stem cells 
(7).  Lgr5 immunostaining marked only an average of 3.5 cells per crypt, suggesting that this 
could be a marker of stem cells and, less likely, a marker of stem and transit amplifying cells 
(7).  The Lgr5-positive cells that reside between Paneth cells have been termed crypt base 
columnar cells (CBCs) and lie at a site where proliferation often takes place (7).  Lineage-
tracing studies in which a tamoxifen-inducible Cre recombinase was knocked-in to the Lgr5 
locus and then crossbred with a transgenic mouse expressing Cre-activated LacZ allowed 
lineage tracing of cells derived from Lgr5 positive cells.  This revealed that Lgr5-positive 
CBCs were able to generate goblet, enterocyte, and Paneth cells (enteroendocrine cells were 
too rare to locate in these studies), indicating that Lgr5-positive cells are multipotent (7).  
Thus, Lgr5/Gpr49 may be a true intestinal stem cell marker. 
   At the same time these studies were being conducted, our laboratory began to turn 
to Sox9, or Sry-related High Mobility Group (HMG)-box DNA binding protein 9, as a 
potential stem cell marker.  The Sox family of transcription factors are composed of 26 
proteins shown to mark stem and progenitor cells in other organs and can enhance or 
antagonize β-catenin/Wnt signaling (186, 218).  Sox9 expression requires the Wnt/β-catenin 
pathway, and Sox9 has been implicated in fate determination of stem cells in other organs, 
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including the nervous system, pancreas, cartilage, and gonads (1, 23, 28, 104, 180).  In 
intestine, Sox9 is normally expressed in the same regions within the crypt where proliferating 
cells reside, indicating Sox9 could mark intestinal stem or progenitor cells (12).  When the 
Sox9 gene is inactivated in mice, Paneth cells failed to form and goblet cell formation was 
decreased (9, 125).  These findings were associated with hyperplasia and dysplasia within the 
intestinal epithelium.  These studies suggest Sox9 plays a crucial role in growth and 
homeostasis of the intestinal epithelium as well as differentiation of two major lineages.  
Furthermore, human adenocarcinoma stains positive for Sox9, indicating a potential role for 
Sox9 in intestinal tumorigenesis (12).  Whether Sox9 is a true stem cell biomarker or plays a 
significant role in intestinal tumors needs to be further explored.  As described in later 
chapters, recent data from our group indicates that Sox9 is expressed in both the CBCs 
(identified as the stem cells by the Clevers group) and the stem/progenitor cell region as 
identified by Potten’s group. 
 
 
D.  Biological significance of crypt apoptosis 
 
The small but significant rate of crypt apoptosis in small intestine and colon is 
thought to serve two potential roles.  Apoptosis may remove ‘excess’ cells and thereby 
ensure that rates of cell production do not exceed rates of cell loss, preserving normal 
epithelial mass and crypt homeostasis.  In addition, apoptosis may remove genetically-
damaged crypt cells, preventing their expansion into a precancerous or cancerous lesion.  
Evidence in support of this concept stems from recent data in humans showing a link 
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between low rates of apoptosis in normal intestinal mucosa and risk of precancerous 
adenomatous lesions in the colon (15, 110).  High proliferation rates of stem or progenitor 
cells may also represent a risk factor for developing colon cancer.  High rates of crypt 
proliferation statistically increase the probability of DNA damage.  Furthermore, the highest 
rates of apoptosis occur near the base of the small intestine or colonic crypts, where crypt 
stem and progenitor cells reside and apoptosis is triggered by DNA damage (72, 217).  
Radiation, which inducees apoptosis of genetically-damaged crypt cells, is a valuable tool for 
signaling mediators of cell death and crypt regeneration (150). 
 
E.  Intestinal cancer 
  
The colon and, to a lesser extent, the small intestine are sites of development of 
precancerous and cancerous lesions.  Perpetual and rapid turnover of intestinal epithelial cells 
may contribute to cancer risk.  As cells divide, newly synthesized DNA is susceptible to the 
introduction of mutations, which can lead to cancer.  In the small intestine, cells that acquire 
genetic mutations often undergo p53-dependent apoptosis, thereby preventing rapid 
expansion of genetically-damaged stem cells (109).  In the large intestine, however, an anti-
apoptotic protein called Bcl-2 is expressed and can prevent apoptosis of genetically-damaged 
cells (114, 117).  Therefore, the colon relies more heavily on DNA repair mechanisms to 
prevent aberrant growth within the epithelium (109).  The colon is also subjected to a greater 
amount of toxins and potentially harmful microbial agents than the small intestine while 
lacking protection by Paneth cell secretions, a combination thought to contribute to the vastly 
greater cancer risk in colon compared to small intestine.   
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Colon cancer is the third most prevalent cancer worldwide (20).  Early detection is 
key to colon cancer survival, since metastasis leads to poor prognosis (45).  Colon cancer is 
curable with surgery, however metastasis occurs in at least 40% of colon cancer patients and 
often requires a combination of surgery, radiotherapy, and chemotherapy (45).  Figure 1.2 
shows the typical progression of colon cancer, with common mutations or risk factors noted 
at specific stages along the pathway.  Mutations in genes such as APC lead to familial 
adenomatous polyposis (FAP) in which hundreds to thousands of tumors cover the colon 
(53).  Other genetic mutations can also be inherited, leading to Hereditary Nonpolyposis 
Colorectal Cancer (HNPCC) (232), while mutations that are acquired and not inherited lead 
to sporadic colon cancer (19).  Microsatellite instability (MSI) resulting from deficient 
function of mismatch repair genes is a hallmark of HNPCC but is also found in 15% of all 
sporadic cancers (41).  Colon cancer is often initiated by mutations that lead to consititutive 
activation of oncogenes, as in the case of K-Ras, which is mutated in about 30-60% of all 
colon cancers (19).  Conversely, silencing of tumor suppressors by hypermethylation can also 
lead to colon cancer, such as hypermethylation of CpG islands in the hMLH1 gene promoter, 
a common mismatch repair gene (48, 224).  The abundance of genes affected by 
hypermethylation have led to a push to decode the DNA “hypermethylome” (48).  Clustering 
of human colon cancers by CpG island methylator phenotype (CIMP) and mutation status 
has recently allowed colon cancer classification into separate subgroups (183).  The three 
groups, CIMP1 (high in MSI and in BRAF mutations), CIMP2 (high in K-Ras mutations), 
and CIMP-negative (high in p53 mutations) subgroups show distinct trends in histology and 
prognosis (183).   
Colonoscopy is used to detect neoplastic lesions, which are removed and biopsied 
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when found.  While adenomas and other pedunculated polyps are typically found and 
removed at the time of colonoscopy, flat or sessile tumors are more difficult to detect (77).  
Since colon cancer is not always easily detected and colonoscopy is a highly-invasive 
procedure, understanding the factors underlying polyp initiation and growth is crucial for 
preventing cancer.   
 
F.  Obesity, insulin and colon cancer 
 
Body mass index and waist to hip ratio both strongly correlate with colon cancer risk 
(16, 63).  This is especially alarming because two thirds of the American population is 
overweight and obesity has risen from 13% to 30% in the last 40 years (63).  Low physical 
activity, high calorie intake, and high glycemic index of foods taken in all correlate with an 
increased risk of colon cancer (63).  Insulin resistance and colorectal neoplasia are linked, but 
whether these two diseases are directly linked or if they simply share similar risk factors is 
not known (63, 179).  Insulin resistance results in high circulating levels of insulin, and this 
excess insulin may have proliferative or tumorigenic potential in the colon since the colon is 
not a typical site of insulin signaling and glucose storage (63, 179).  Increased energy intake 
may also link to colon cancer due to an increase in triglycerides and fat metabolites, which 
can regulate gene transcription through PPARγ in colonic tissue and play a role in growth 
and insulin sensitivity (42, 78, 170, 191).  Intracellular lipids may also increase cancer risk 
by serving as substrates for oxidative stress, depleting available antioxidants, and leading to 
DNA damage (43, 63).  Recent studies in our laboratory and that of Dr. Robert Sandler 
showed that high but within the normal range insulin increased risk of precancerous 
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adenomatous polyps and strongly correlated with low rates of crypt apoptosis in humans 
(85).  Furthermore, insulin levels and obesity perturb circulating levels of insulin-like growth 
factors (IGFs), either directly or by affecting levels of IGF binding proteins (IGF-BPs) that 
modulate the bioavailability of IGFs (63).  Numerous components of the IGF system of 
growth factors are implicated throughout the progression to colon cancer, as shown in Figure 
1.2.  
 
G.  The growth hormone/insulin-like growth factor axis 
 
Overview:  Growth hormone (GH) is secreted in a pulsatile manner, with low 
secretion pre-puberty, a rise during puberty, and a drop at old age (101).  GH releasing 
hormone (GHRH) is produced in the hypothalamus and stimulates the production of GH in 
the anterior pituitary, which is released into the circulation.  Circulating GH binds the GH 
receptor (GHR) and stimulates the production of IGF-I primarily in the liver, although GH 
can act on other organs, including the intestine to increase IGF-I expression (143).  Evidence 
suggests that Signal Transducer and Activator of Transcription 5b (STAT5b) is a key 
mediator of GH-induced IGF-I production in liver, since STAT5b knockout mice show 
decreased body growth and serum IGF-I levels and fail to increase liver IGF-I expression 
upon stimulation with GH (34, 198, 206, 220). GH production by the pituitary gland is 
limited by IGF-I via a classical negative feedback mechanism (143).  The IGF system is 
summarized in Figure 1.3.   
IGF system ligands (IGF-I, IGF-II, and insulin):  Insulin is synthesized only by 
beta cells in the pancreas.  Available evidence suggests that the IGFs are produced by 
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hepatocytes in liver and by mesenchymal cells (fibroblasts, myofibroblasts, smooth muscle 
cells) in multiple organs (65, 219).  In the intestine, mesenchyme-derived IGF-I can stimulate 
growth of the epithelium (216).  IGF-I and IGF-II are single-chain polypeptides with 70% 
homology in amino acid sequence (75).  Both IGF-I and IGF-II contain B, A, C, and D 
domains as well as a carboxyl-terminal E domain that is cleaved off in the golgi prior to its 
trafficking (97).  Proinsulin contains B, C, and A domains and, in contrast to the IGFs, the C 
domain is cleaved from proinsulin during post-translational processing so that insulin 
contains only the B and A chains linked by disulfide bonds (97).  The portion of proinsulin 
that is cleaved off, named C-peptide, is secreted with mature insulin and is a commonly-used 
marker of insulin secretion (63). Since rodents express IGF-II primarily at the fetal stage, it 
was previously thought that IGF-II functions in fetal growth while IGF-I functions 
postnatally.  In humans, however, IGF-I and IGF-II is produced in multiple organs 
throughout life with IGF-II in consistently higher abundance than IGF-I (97).  Transcription 
of IGF-II from its first promoter site is found in adult tissue while transcription from its third 
and fourth promoter sites is found in fetal tissue (234).  
Insulin and IGF receptors:  The actions of IGF-I, IGF-II, and insulin are mediated 
by two receptors, the IGF-IR and the insulin receptor (IR).  Activation of the IGF-IR by IGF-
I or IGF-II or insulin activation of the IGF-IR or IR transduces most of the growth-promoting 
effects of the IGF system.  The IGF-IIR (or mannose-6-phosphate receptor) specifically 
binds IGF-II and no other ligands and functions as a scavenger receptor, binding IGF-II and 
diminishing its action (211, 229).   
 The 60% homologous IGF-I and insulin receptors are both heterotetramers, 
containing 2 α extracellular subunits and 2 β transmembrane subunits linked by disulfide 
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bonds (211).  The α subunits are mainly involved in ligand binding whereas the β subunits 
include a tyrosine kinase domain involved in transmitting various downstream signals.  IGF-I 
binds the IGF-IR with at least 2 times greater affinity than IGF-II (82), which is thought to 
contribute to the greater role of IGF-I in adulthood compared to IGF-II, despite the overall 
higher levels of IGF-II.  IGF-I also has 2 times greater affinity for the IGF-IR compared to 
the insulin receptor (IR), but physiological levels of IGF-I can activate the insulin receptor 
since IGF-I circulates at 10-100 times the concentration of insulin (99).  Generally, 
circulating IGF binding proteins (IGFBPs) sequester IGF-I and prevent binding to the IR.  
The insulin receptor has two isoforms, an isoform that lacks exon 11 (IR-A) and an isoform 
that includes exon 11 (IR-B).  IR-A has high affinity for IGF-II and is currently regarded as 
the receptor involved in proliferative effects of insulin and IGF-II, whereas the IR-B 
primarily binds insulin and mediates the metabolic actions of insulin on glucose and fat 
storage (165).   
 The IGF-IR and IR can heterodimerize forming hybrid receptors.  The IGF-IR/IR 
hybrids have high affinity for IGF-I, but low affinity for insulin.  This decreased response to 
insulin with an increase in IGF-IR/IR hybrid formation has been proposed as the mechanism 
behind insulin resistance in type 2 diabetes mellitus (99).  Hybrids composed of the different 
isoforms of the IR act differently, with IGF-IR/IR-A binding IGF-I, IGF-II, and insulin, 
while IGF-IR/IR-B binds IGF-I, IGF-II to a lesser extent, and does not bind insulin (142). 
 IGF binding proteins:  IGF bioavailability and action is modified by a family of six 
or more IGF binding proteins.  The majority of IGF-I and IGF-II in the circulation is bound 
to an IGFBP, influencing the bioavailability of ligand (168).  The majority of IGF-I and IGF-
II is bound to IGFBP-3 along with an 80-kd acid-labile subunit (168).  The IGFBPs increase 
  14 
 
the half-life of circulating IGFs, sequester IGFs in the blood vessels, and control their 
availability to their receptors (99, 168).  Some IGFBPs, however, facilitate selective transport 
to specific organs by allowing the ligand to cross capillary walls or directly interact with their 
receptors thereby augmenting receptor binding of the ligand (99, 168).  Insulin does not bind 
IGFBPs, but can decrease the production of IGFBP-1 and IGFBP-2 (168).  IGFBP proteases 
can hydrolyze IGFBPs and release the ligand from its binding partner, allowing it to become 
biologically active (231).  Therefore, the IGF-IIR (which scavenges IGF-II) and IGFBPs 
negatively regulate the actions of the IGF system, whereas the IR, the IGF-IR, and IGFBP 
proteases can be regarded as positive regulators of the pathway.   
 
H.  IGF-IR and IR signaling 
 
IGF-I or IGF-II binds to the extracellular α subunit of the IGF-IR, resulting in a 
conformational change and cross-autophosphorylation of the intracellular β subunits (99).  
This leads to further phosphorylation of tyrosine residue sites in the juxtamembrane and 
COOH-terminal regions of the receptor, which can then recruit downstream docking proteins 
such as insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) and src homology-containing 
and collagen-related protein (Shc) (99).  These signaling molecules can then activate the PI-3 
kinase and Ras/Raf/mitogen-activated protein kinase (MAPK) signaling cascades that 
eventually lead to the proliferative, apoptotic, and differentiative effects of IGF-I (93, 95, 
173, 202).  Although in cell lines IGF-I, IGF-II or insulin can activate both IRS-1 and IRS-2, 
findings in IRS-1 and IRS-2 knockout mice indicate a preferential role of IRS-1 in growth 
and a preferential role of IRS-2 in metabolism.  IRS-1 knockout mice exhibit reduced body 
  15 
 
growth and reduced growth of several organs including the intestine but do not develop type 
2 diabetes (5, 145), while IRS-2 null mice show normal body and organ growth but do 
develop type 2 diabetes (212).  In other tissues, studies indicate a preferential role of IRS-1 
compared with IRS-2 in mediating the growth-promoting and anti-apoptotic actions of 
insulin (159, 196). 
 
I.  IGFs and IRS-1 in anti-apoptotic pathways 
 
IGF/IGF-IR/IRS-1 link directly to numerous anti-apoptotic pathways, defined 
primarily in cancer cell lines.  The PI3K/Akt pathway is often considered the central pathway 
in inhibition of apoptosis by IGF-I (93).  IGF-I-induced activation of Akt promotes 
phosphorylation of FKHRL1 and FKHR, members of the forkhead family of transcription 
factors, causing cytoplasmic retention (173).  This reduces transcriptional activity by 
Forkhead proteins, putatively by recruitment of 14.3.3., which masks the nuclear localization 
signal and DNA binding site (93, 173).  Unphosphorylated nuclear Forkhead proteins, 
however, can activate transcripton of pro-apoptotic proteins, such as FasL, Bim, TRAIL, and 
TRADD (93, 173).  IGF-I induces Bcl-2 and Bcl-XL, which are anti-apoptotic if 
homodimerized or pro-apoptotic if heterodimerized with unphosphorylated Bad (93).  IGF-I 
also promotes cell survival by stimulating phosphorylation of Bad via Akt/PKB, preventing it 
from heterodimerizing with Bcl-XL (29, 93).  IGF-I induces mTOR, which phosphorylates 
the cell growth-promoting 4EBP protein and S6 kinase, which is involved in ribosome 
biogenesis (100).  
Following DNA damage in cultured fibroblasts, IGF-I opposes apoptosis by 
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stimulating p53 degradation (69).  In myocytes, inhibition of apoptosis by IGF-I correlated 
with decreased p53 expression and an increase in mdm2, a RING finger ubiquitin ligase that 
targets p53 for degradation (98).  In hepatoma, melanoma, intestinal smooth muscle cells and 
colon cancer cell lines, IGF-I inactivates glycogen synthase kinase-3 (GSK-3) and activates 
Tcf/β-catenin pathways (37, 95, 147).  IGF-I also interacts with α-catenin and E-cadherin in 
mediating migration and invasion in colon cancer cell lines (4).  Though previously thought 
of as strictly an anti-apoptotic signaling molecule, ERK activation by IGF-I has been shown 
under various conditions to promote apoptosis, possibly by inducing cytochrome c release 
and caspase 3 activation or by inhibition of the pro-survival Akt pathway (236).  IGF-I and 
IGF-II induce Cox-2 and prostaglandin E2, which are increasingly implicated in the 
enhanced proliferation and decreased apoptosis in intestinal adenoma and colon cancer, as 
well as in other systems (39, 74, 87, 148, 182).  IRS-1 activation has been found in various 
tumor types, and its inhibition leads to a less transformed phenotype in a breast cancer cell 
line (24, 91).  Furthermore, studies show that a G972R polymorphism in the IRS-1 gene had 
a significant association with increased risk of adenoma and colorectal cancer (CRC) (187), 
further supporting a major role of IRS-1 in cancer.  Given the major role of IRS-1 in 
mediating the anti-apototic actions of insulin and IGFs, known risk factors for colon cancer, 
this prompted the emphasis of IRS-1 studies described here (Chapter II). 
 
J.  The role of the APC gene in intestine 
 
The Wnt signaling pathway is involved in growth and development of epithelial cells, 
including the intestinal epithelium (131).  In the absence of a Wnt signal, a multiprotein 
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complex comprised of adenomatous polyposis coli (APC), glycogen synthase kinase 3β 
(GSK3β), and axin binds β-catenin and targets it for destruction in the proteosome (131).  
When Wnt ligands are present, they bind the frizzled receptor and inhibit GSK3β, preventing 
GSK3β from binding APC and axin (131).  Under these conditions, β-catenin is not 
degraded, accumulates in the cytoplasm, and translocates to the nucleus to serve as a co-
activator of transcription once bound to the T-cell factor 4 (TCF4) transcription factor (201).  
Various cell cycle progression genes are transcriptionally activated under these conditions, 
including Cyclin D and Myc, providing favorable conditions for the intestinal epithelium to 
undergo neoplastic growth (76). 
Mutations in the APC gene are an early and common event in colon cancer, occurring 
in approximately 85% of spontaneous colon cancers (228).  Hereditary intestinal polyposis in 
familial adenomatous polyposis (FAP) and Gardner syndrome are also caused by APC gene 
truncations (14, 53).  ApcMin/+ mice are heterozygous for an APC truncation mutation, but 
through a process called loss of heterozygousity (LOH), some cells lose their wildtype allele 
and become homozygous for this mutation (25).  Cells that have undergone LOH have 
dysregulation of cellular β-catenin, leading to tumor formation (92).  The ApcMin/+ mouse 
model is caused by a truncation in codon 850, which leads to loss of the GSK3β binding site 
in the APC gene protein product (128).  As shown in Figure 1.4, mutated Apc is unable to 
bind GSK-3β and β-catenin is not degraded, much like in the presence of Wnt ligand (228).  
Thus, ApcMin/+ mice have tens to hundreds of adenomatous polyps preferentially localized, 
but not limited to, the small intestine. This mouse model can be used to study factors that 
contribute to or protect against precancerous lesions in the intestine.  A Cre-lox inducible 
mouse model was made to more directly test the role of APC in the intestinal epithelium 
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(169).  APC deletion in this mouse model resulted in perturbed differentiation, increased 
proliferation, and disrupted migration of intestinal epithelial cells along the crypt/villus axis, 
all of which are considered phenotypic hallmarks of intestinal neoplasia (169).  
Recent reports indicate direct interactions between IRS-1 and β-catenin.  Studies in 
C10 cells (a colorectal cancer cell line) show that IGF-IR binds E-cadherin and β-catenin at 
the membrane, forming a complex that disassembles upon IGF-IR activation (147).  In the 
presence of IGF-I, β-catenin is released from the membrane, shows an increased half-life, 
and can enter the nucleus to serve as a transcriptional cofactor.  Other in vitro studies using 
fibroblasts derived from mouse embryos with targeted disruption of IGF-IR, with and 
without stable transfection of IGF-IR, indicate that IRS-1 directly associates with β-catenin.  
Furthermore, IRS-1 appears to be involved in nuclear translocation of β-catenin, and IRS-
1/β-catenin complexes can bind to the promoters of growth promoting target genes of β-
catenin that mediate proliferation or apoptosis (26).  Given the in vitro evidence for an 
interaction between IRS-1 and β-catenin, studies in Chapter II aimed to assess if IRS-1 
deficiency altered ApcMin/+ tumorigenesis in vivo. 
 
K.  The SOCS family of proteins 
 
Other portions of this thesis (Chapters III and IV) focus on Supressor of Cytokine 
Signaling-2 (SOCS2) as a negative regulator of the GH/IGF axis in the intestine.  The family 
of SOCS proteins consists of SOCS 1-7 and CIS (cytokine inducible SH2-containing protein) 
(60).  SOCS proteins are activated by various cytokines and growth factors, most commonly 
those that signal through the janus kinase and signal transducer and activator of transcription 
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(JAK/STAT) pathway (60, 61).  Various SOCS family members have also been shown to 
bind and inhibit various cytokine and growth factor signaling receptors, including GHR as 
shown in Figure 1.5 (61).  SOCS proteins, particularly SOCS1 and SOCS3, have been shown 
to bind and inactivate JAKs, which are recruited to the receptor following its activation by 
ligand binding. Upon activation, cytokine receptors dimerize and bind JAKs, which 
autophosphorylate and activate the receptor at specific tyrosine residues. These residues 
serve as docking sites for STATs, which become phosphorylated, dimerize, and enter the 
nucleus and serve as transcription factors for various target genes, including SOCS (60).  By 
binding the receptor, SOCS can compete with STATs for binding sites on the activated 
cytokine receptor, thereby diminishing receptor signaling.  SOCS proteins contain an N-
terminus of variable homology, a central SH2 domain, and a conserved 40 amino acid motif 
near the C-terminus called the SOCS box.  The SH2 domain binds phosphotyrosine sites on 
activated proteins, and the SOCS box interacts with elongins B and C, likely targeting 
activated proteins for destruction in the proteosome (21, 83, 233). This targeted degradation 
has been proposed as one of the ways SOCS proteins may terminate cytokine signaling.  To 
date, most is known about the functions of SOCS1, SOCS2, and SOCS3.  Generation of mice 
with targeted disruption of SOCS1 and SOCS3 genes indicates a role of SOCS1 in regulating 
IFNγ action and a role of SOCS3 in IL-6 signaling.  Both these SOCS are therefore key 
negative modulators of signaling by immune cell-derived cytokines (60).  Unlike SOCS1 and 
SOCS3, SOCS2 has been shown to play a limited role in immune function but plays a major 
role in growth. 
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L.  SOCS2 as an inhibitor of the GH/IGF-I axis 
  
SOCS2-/- mice display increased body weight, similarly to GH-transgenic mice, 
suggesting that SOCS2 may play a role in GH signaling (61).  When SOCS2-/- mice were 
crossed with growth hormone releasing hormone receptor deficient mice (Ghrhr-/-), GH-
deficient or “little” mice, GH-deficiency reversed the overgrowth phenotype of the SOCS2-/-  
(61).  These SOCS2-/-/Ghrhr-/- double-mutants were also hyper-responsive to exogenous GH, 
and GH administration recapitulated the SOCS2-/- phenotype, suggesting increased growth 
from SOCS2 deficiency is dependent on GH action (61).  Data in yeast two-hybrid screens 
indicate that SOCS2 binds directly to both the activated GH and IGF-I receptors (38, 66).  
Recent data from our lab shows that FLAG-tagged SOCS2 associates with activated 
endogenous IGF-I receptor in Caco2 colon cancer cells and attenuates IGF-I induced 
activation of the IGF-IR and IRS-1 (120).  Furthermore, in Caco2 cells, SOCS2 expression 
increases as cells become confluent and overexpression of SOCS2 limits proliferation and 
induces expression of enterocyte differentiation markers (121).  In IEC-6 cells (an 
untransformed rat intestinal epithelial cell line that, unlike Caco-2 cells, are GH-responsive) 
GH treatment led to induction of SOCS2 mRNA, a decline in cellular proliferation, and also 
attenuated IGF-I-induced proliferation (121).  Crypts isolated from SOCS2 knockout mice 
were more responsive to both GH and IGF-I (121).  Together, these data support the novel 
concept that SOCS2 limits the actions of IGF-I and the IGF-IR tyrosine kinase as well as 
having a more traditional role in limiting the actions of the cytokine GH.   
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M.  SOCS proteins in colon caner 
 
Inflammatory bowel disease (IBD) has been linked to an elevated risk of colorectal 
cancer, which is likely due to chronic inflammation of the intestinal mucosa (62, 77, 194).  
Cytokines and growth factors can help repair damage and restore the absorptive and barrier 
function of the intestinal epithelium, but such actions can lead to hyperplasia and predispose 
to dysplasia or neoplasia.  GH and IGF-I are key mediators of mucosal repair during 
inflammation, and SOCS proteins may limit their actions to prevent an excessive wound 
healing response (194).  SOCS proteins have been implicated in IBD, particularly SOCS3.  
SOCS3 was shown to be induced by GH treatment in a peptidoglycan-polysaccharide rat 
model of IBD and fibrosis, and SOCS3 mRNA was localized to granulomas, suggesting that 
SOCS3 may mediate anti-inflammatory or anti-fibrogenic roles of GH (194).  Our laboratory 
has shown that intestinal epithelium-specific knockout of SOCS3 can increase the 
susceptibility to inflammation-induced intestinal tumor formation using the 
azoxymethane/dextran sodium-sulfate (AOM/DSS) model.  Thus, SOCS3 may be crucial in 
promoting the beneficial effects of GH/IGF-I during mucosal repair in IBD, while limiting 
excessive trophic effects that could favor neoplastic growth (194).  Although SOCS2 was 
recently shown to be required for the anti-inflammatory action of lipoxins, very little is 
otherwise known about the mechanisms and extent of SOCS2 activity in the immune system 
(105, 160).  Whether SOCS2 can alter the risk of CRC by playing a similar role in the 
inflammatory process has yet to be fully explored.  
Endogenous growth hormone is crucial for both normal intestinal growth during 
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development and during adaptive growth following loss of mucosal surface area (143).  
Recombinant GH is an FDA-approved treatment for stunted growth in GH-deficient children 
and for patients with short bowel syndrome (SBS), a bowel malabsorption syndrome 
following multiple surgeries (70).  However, excess growth hormone has been implicated in 
various cancers, including colon cancer.  Acromegalics, who have GH-secreting pituitary 
tumors resulting in elevated GH and IGF-I levels, have increased risk of colorectal cancer, 
although the extent of this increased risk remains controversial (80).  The role of SOCS2 in 
inhibiting GH/IGF-I action supports a role for SOCS2 in protecting against colon cancer by 
inhibiting excessive trophic effects of GH.  Data showing that SOCS2 gene inactivation by 
hypermethylation of CpG islands within the SOCS2 promoter region correlates with multiple 
types of cancer support a role for SOCS2 in cancer development (30, 49, 52, 68, 190, 203).  
Despite an accumulating literature on SOCS2 epigenetic silencing in cancer of a number of 
organs, little direct evidence to-date indicates a direct role for SOCS2 in colon cancer or 
cancer of other organs.  Thus, elucidating the role of SOCS2 in intestinal tumorigenesis was 
a key objective of the studies described here. 
 
N.  Hypotheses tested by the studies presented in this dissertation 
 
I. IRS-1 protects against irradiation-induced apoptosis in the intestinal crypt stem 
cell zone.  Studies testing this hypothesis are described in Chapter II. 
II. IRS-1 promotes intestinal adenoma number and size in the ApcMin/+ model of 
intestinal polyposis.  Chapter II also describes studies testing this hypothesis. 
III. SOCS2 limits the growth-promoting actions of GH in the intestine and prevents 
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the formation of GH-induced aberrant lesions in intestine.  These studies are 
described in Chapter III. 
IV. SOCS2 limits sporadic and/or inflammation-associated lesions in intestine.  These 
studies are tested in Chapter IV.   
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Figure 1.1. Structure of the gastrointestinal tract A.  Schematic shows the layers of the 
gastrointestinal tract wall.  B.  Schematic shows the architecture of the small (left) and large 
(right) intestine. 
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Figure 1.2.  Adapted from the ‘Vogelstein model of carcinogenesis.”  Common contributing 
factors in colon cancer are noted at the top, with the role of the IGF system shown at the 
bottom. 
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Figure 1.3. The IGF system.  Schematic illustrates the IGF system, including ligands, 
receptors  and relative binding affinities noted under each receptor. 
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Figure 1.4. β-catenin signaling.  Schematic shows the regulation of cellular β-catenin, 
illustrating its role at the membrane, its degradation in the cytoplasm, and its accumulation 
when the Apc gene is truncated.  When β-catenin is allowed to accumulate, it translocates 
into the nucleus, where it functions in transcription of Wnt targets and various cell cycle 
progression genes, including Sox9, Myc, and Cyclin D. 
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Figure 1.5. GH and SOCS2 signaling.  Diagram illustrates GH signaling through the 
JAK/STAT pathway, leading to transcription of SOCS2, and the putative mechanisms of 
inhibition by SOCS2. 
 
 
 
 
  
 
CHAPTER II 
 
IRS-1 DEFICIENCY PROMOTES APOPTOSIS IN THE PUTATIVE INTESTINAL 
CRYPT STEM CELL REGION, LIMITS APCMIN/+ TUMORS, AND REGULATES 
SOX9 
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A.  Introduction 
 
  The epithelial lining of the small and large intestine is constantly renewed as a result 
of continuous proliferation of putative intestinal stem cells and progenitor cells within the 
crypts (11, 172). While the identity of intestinal stem cells is not conclusively defined, 
current evidence suggests that they reside near the base of the crypts (11, 172).  As well as 
continuous proliferation, there are small but significant levels of spontaneous apoptosis in the 
crypts.  Genotoxins such as gamma irradiation lead to major increases in crypt apoptosis, and 
this effect is particularly pronounced in the region of the putative crypt stem cells and 
progenitors (150).  The radiosensitivity of intestinal stem cells is thought to protect against 
tumor development by reducing the probability of clonal expansion of genetically damaged 
stem cells (6, 150).  A better understanding of the key modulators of irradiation-induced 
apoptosis could provide critical insight into potential cancer risk factors or point to new 
therapies.  In animal models, insulin-like growth factors (IGFs) reduce spontaneous or 
irradiation-induced crypt apoptosis, with effects being especially potent in the putative crypt 
stem cell region (215).  Human studies show that low rates of spontaneous apoptosis in 
normal intestinal crypts predict increased risk of precancerous adenomas in the colon (85, 
110). Multiple studies have linked increased plasma or tissue IGFs to increased risk of 
intestinal cancer in humans (46, 56, 166, 221).  Our recent studies indicate that high but 
within the normal range levels of insulin in humans correlate strongly with both low 
apoptosis in intestinal crypts and increased adenoma risk (15, 85).  
This study focuses on insulin receptor substrate-1 (IRS-1), because it is a key 
mediator of the actions of both insulin and the IGFs and lies downstream of the insulin and 
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IGF-I receptors (161).  Considerable evidence indicates that IRS-1 is a primary mediator of 
the anti-apoptotic or trophic actions of insulin and the IGFs (161, 213).  IGFs and insulin can 
also activate IRS-2, but findings in IRS-1 and IRS-2 null mice suggest preferential roles of 
IRS-1 in growth and IRS-2 in metabolism.  IRS-1 null mice exhibit reduced body growth and 
reduced growth of several organs including the intestine (145), while IRS-2 null mice are 
normal size but develop type 2 diabetes (5, 212).   
Accumulating evidence links IRS-1 to cancer.  A G972R polymorphism in the IRS-1 
gene significantly increased risk of colorectal cancer (187).  IRS-1 is overexpressed or 
constitutively active in a number of cancers and cancer cell lines, including colon cancer cell 
lines (24, 91, 134).  Recent studies demonstrate that mice with mammary gland-specific IRS-
1 overexpression develop spontaneous metastatic mammary tumors (35).  Whether reduced 
expression of endogenous IRS-1 can protect against cancer of any organ, including colon 
cancer, remains unknown.  The present study tested the hypothesis that reduced levels of 
endogenous IRS-1 promote apoptosis of genetically-damaged crypt stem or progenitor cells 
in the intestine and protect against spontaneous intestinal adenoma.  Our studies focused on 
the role of IRS-1 in spontaneous intestinal tumors driven by excessive activation of β-
catenin-mediated transcription, since accumulating evidence suggests that the IGF-I receptor 
activates β-catenin via IRS-1 dependent pathways (26, 35, 147, 222). 
ApcMin/+ mice have a truncation in Apc (adenomatous polyposis coli), a gene mutated 
in many human intestinal cancers (226).  ApcMin/+ mice spontaneously develop tens to 
hundreds of adenomas in small intestine and some adenomas in colon (127).  Adenomas have 
aberrant intracellular and nuclear accumulation of β-catenin, which is normally degraded by 
an APC-containing complex (228).  β-catenin acts in concert with Tcf/Lef transcription 
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factors to activate genes that regulate crypt cell proliferation and survival (76).  By 
crossbreeding, we developed ApcMin/+ mice with IRS-1+/+, IRS-1+/-, and IRS-1-/- genotypes to 
determine if partial or absolute IRS-1 deficiency reduces susceptibility to spontaneous 
intestinal tumors driven by β-catenin. 
Defining IGF-IR/IRS-1 regulated biomarkers of intestinal stem cells could be relevant 
to defining mechanisms or biomarkers for increased intestinal cancer risk due to elevated 
levels of IGF or insulin.  The Sry-related High Mobility Group (HMG)-box DNA binding 
protein (Sox9) is a β-catenin/Tcf gene target implicated in fate-determination of stem cells in 
the pancreas, neural ectoderm, cartilage, and gonads (1, 12, 23, 28, 104, 180).  In intestine, 
recent studies demonstrate that Sox9 localizes to the nucleus of proliferating crypt cells, 
particularly in regions where stem or progenitor cells reside (12).  Sox9 also represses 
expression of intestinal differentiation markers Muc2 and Cdx2, suggesting a role for Sox9 in 
maintenance of an undifferentiated stem or progenitor phenotype (12).  Sox9 is highly 
expressed in human colon cancer cell lines and in intestinal tumors (12), indicating a possible 
role in tumorigenesis.  Studies in chondrocytes indicate that Sox9 expression is induced by 
IGF-I (181), but whether this occurs in other cell types or is IRS-1 dependent is unknown.  
Our studies therefore explored whether changes in the number of Sox9 positive cells or Sox9 
expression levels in crypts were associated with the effects of IRS-1 genotype on adenoma 
susceptibility in the ApcMin/+ mice, and if increased IRS-1 expression in intestinal epithelial 
cells alters Sox9 expression in vitro. 
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B.  Materials and Methods 
 
Mouse models   
Mice heterozygous for targeted disruption of the IRS-1 gene (IRS-1+/-) on a pure-bred 
C57BL/6 background were previously described (5) and provided by Dr. Ronald Kahn.  IRS-
1+/- males and females were bred to derive sex-matched littermates with 2 (IRS-1+/+), 1 (IRS-
1+/-), or 0 (IRS-1-/-) functional IRS-1 alleles for studies of spontaneous and irradiation-
induced apoptosis. ApcMin/+ male mice on the C57BL/6 background were obtained from 
Jackson Laboratories (Bar Harbor, ME) and crossed with female IRS-1+/- mice.  IRS-1+/- 
males with the ApcMin/+ mutation were then crossbred with IRS-1+/- females.  This two-step 
crossbreeding yielded ApcMin/+ and wildtype (WT) mice with 2, 1, or 0 functional IRS-1 
alleles.  Genotyping was performed on tail DNA using primers described previously (145, 
163).  Studies in ApcMin/+ mice were largely confined to females since males were used 
primarily for breeding.  All animal studies were approved by the Institutional Animal Care 
and Use Committee of the University of North Carolina.  Study protocols were in compliance 
with the Guide for the Care and Use of Laboratory Animals published by the NIH. 
 
Irradiation and tissue collection   
Mice (50-75 days old) received 5 Gy of whole body irradiation delivered at 1 Gy/min 
with a 137Cs source and were killed four hours after irradiation, a time of peak irradiation-
induced apoptosis (152).  Non-irradiated, genotype- and sex-matched littermates were used 
as controls.  Mice were anesthetized using sodium pentobarbital (200 µg/g body weight), and 
the abdomen was opened by mid-line incision.  Two pieces of jejunum (each 0.5-cm long) 
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were fixed in 10% formalin for four hours, dehydrated in 70% ethanol, and embedded in 
paraffin. 
 
Analysis of apoptosis in irradiated mice   
Apoptosis was quantified in hematoxylin and eosin (H&E)-stained 4µm sections of 
jejunum as previously described (215).  Briefly, morphological identification of apoptotic 
crypt cells was based on nuclear margination, chromatin and cytoplasmic condensation, 
shrinkage from neighboring cells, and the formation of apoptotic bodies due to nuclear and 
cytoplasmic fragmentation.  Apoptosis in well-oriented crypts was recorded as previously 
described (149), with cells at the base designated as position 1.  All scoring was performed 
twice by a single investigator unaware of the mouse genotype or treatment.  Apoptosis was 
expressed as the mean number of apoptotic cells per crypt or the percent of apoptotic cells at 
each position from the crypt base relative to the total number of cells counted. 
 
Tissue collection and evaluation of tumors in Apcmin/+ mice 
Mice were studied at 18-20 weeks of age, when they were anesthetized and blood 
collected by cardiac puncture.  Since ApcMin/+ mice develop severe anemia as disease 
progresses (67), hematocrit was measured as an indirect marker for tumor load and disease 
severity.  Hematocrit was assayed by the Animal Clinical Chemistry Facility in the Pathology 
Department, University of North Carolina at Chapel Hill.  The entire small intestine and 
colon were dissected, and tumor load was assessed as in prior studies (163).  Briefly, tumor 
number was counted under a Leica dissecting scope for the entire small intestine and colon, 
and tumor diameter was measured using an in-lens micrometer.  Tumor load was calculated 
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by multiplying the total tumor number and mean size for small intestine and colon of each 
mouse.  Intestinal segments were rolled into swissrolls, paraffin-embedded, and sectioned at 
7µm.  The presence and morphology of adenomas were then confirmed by H&E staining and 
β-catenin immunostaining.  Elevated cytoplasmic and nuclear β-catenin is considered a 
reliable hallmark of adenomatous lesions in ApcMin/+ mice (163).  
  
Localization of β-catenin and Sox9   
β-catenin immunostaining was performed as previously described (163).  A primary 
mouse monocolonal β-catenin antibody (BD Transduction Laboratories, #610154, Franklin 
Lakes, NJ) was used together with a biotinylated anti-mouse IgG from the MOM kit using a 
mouse on mouse blocking protocol (Vector Laboratories, Burlingame, CA).  Peroxidase was 
visualized under brightfield using a Nikon Microphot FXA microscope.  For Sox9, a rabbit 
polyclonal antibody (Chemicon, AB35535, Temecula, CA) was used at 1:100, followed by 
peroxidase or a Cy3 labeled secondary antibody at 1:100.  Fluorescent images were taken 
under a Zeiss 510 laser-scanning confocal microscope. 
 
 Northern blot hybridization of Sox9 mRNA   
Total mRNA was extracted from 2 cm of proximal ileum using TriZol reagent 
(Invitrogen, Carlsbad, CA) and manufacturer’s instructions.  Northern blot hybridization was 
performed as previously described (137), using a [32P]CTP-labeled Sox9 DNA template from 
pCMV-SPORT6 (Open Biosystems, Hunstville, AL).  Blots were reprobed for constitutively 
expressed 18S ribosomal RNA, and hybridization signals were visualized using a 
PhosphorImager (Typhoon, GE Healthcare, Piscataway, NJ) as previously described (121). 
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Effects of IRS-1 on Sox9 expression 
Primary cultures of intestinal epithelial cells do not remain viable for sufficient times 
after isolation to study the role of IRS-1 in Sox9 expression.  We therefore used the non-
transformed intestinal epithelial cell line, IEC-6, to assess whether IRS-1 overexpression 
altered Sox9 expression.  IEC-6 cells were grown as previously described (121).  IEC-6 cells 
were infected with either IRS-1 adenovirus (Adex1CAIRS-1wt) (199) or an empty virus 
(Gene Therapy Center Virus Vector Core, University of North Carolina at Chapel Hill) at 108 
particles/mL 18 hours prior to harvesting.  Total cell lysates were prepared, and equal 
amounts of protein subject to SDS-PAGE as described (185).  Blots were incubated in Sox9 
antibody (1:1000), followed by an IRDye 800CW goat anti-rabbit secondary antibody 
(1:5000, #926-32211, LI-COR Biosciences, Lincoln, NE).  b-actin was used as a loading 
control.  Blots were imaged using the Odyssey infrared imaging system (LI-COR 
Biosciences, Lincoln, NE). 
 
Statistical analyses  
Values are expressed as mean ± SEM.  ANOVA was used to compare levels of 
apoptosis in irradiated IRS-1+/+ versus IRS-1+/- or IRS-1-/- littermates and post hoc anaylses 
between each genotype were performed by Fisher’s protected least squares difference 
comparisons.  Wilcoxon signed-rank test was used to compare tumor number, size, and load 
in IRS-1+/+/Min and IRS-1+/-/Min littermates.  IRS-1-/-/Min mice were born at lower than 
expected Mendelian frequency, and it was not possible to restrict comparisons to littermates.  
Therefore, a student’s t-test  was used to compare tumor number, size, and load in IRS-1-/-
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/Min mice versus age- and sex-matched IRS-1+/+/Min or IRS-1+/-/Min mice.  Two-way 
ANOVA was used to determine whether there was significant effect of IRS-1 or Min 
genotype on Sox9 expression and if IRS-1 and Min genotype show a significant interaction.  
p<0.05 was considered to be statistically significant.  
 
C.  Results 
 
IRS-1 gene-dosage effects on irradiation-induced apoptosis of crypt stem cells   
Gamma irradiation induces genetic damage and apoptosis in the intestinal crypts 
(215). Disruption of one or both IRS-1 alleles significantly increased irradiation-induced 
apoptosis (Figure 1a).  After irradiation, IRS-1+/- mice had significantly higher crypt 
apoptosis (2.1 ± 0.17) compared with IRS-1+/+ littermates (1.3 ± 0.09 p=0.019), and IRS-1-/- 
mice had even higher rates of apoptosis (2.5 ± 0.30 p=0.002). 
Prior evidence indicates that small intestinal crypt stem and progenitor cells are 
located primarily at cell positions 3-5 from the base of the crypts, otherwise known as the 
stem cell region (150, 215).  This region lies immediately above Paneth cells which are 
located at the crypt base (cells 1 and 2 relative to the base of the crypts).  Recent studies 
indicate that stem cells may also lie near the base of the crypts interspersed with Paneth cells 
(7).  In IRS-1-/- mice, irradiation-induced apoptosis was significantly increased at positions 2-
7 from the crypt base.  In IRS-1+/- mice, apoptosis was increased significantly at positions 4 
and 6 (Figure 1b).  Thus, partial or absolute IRS-1 deficiency promotes apoptosis of 
genetically-damaged crypt cells, with most dramatic effects within the putative 
stem/progenitor cell region. 
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IRS-1 gene-dosage effects on tumor number in Apcmin/+ mice 
ApcMin/+ mice with disruption of just one IRS-1 allele (IRS-1+/-/Min) had a significant 
24.5 ± 13.0% reduction in the number of small intestinal adenomas compared with sex-
matched IRS-1+/+/Min littermates (p=0.017, Figures 2 and 3).  This is despite the fact that 
loss of one IRS-1 allele has no discernible effect on growth or size of small intestine (145).  
IRS-1-/-/Min mice had a 55.5 ± 13.2% reduction in the number of small intestinal adenomas 
compared with IRS-1+/+/Min mice, an effect which is greater than the 25% reduction in small 
intestine mass observed in IRS-1-/- mice (145).  In colon, IRS-1+/-/Min showed a 46.9 ± 
15.2% decrease, and IRS-1-/-/Min a 61.9 ± 19.0% decrease in adenoma number compared 
with IRS-1+/+/Min mice (Figure 3).  There was a small but significant decrease in adenoma 
size in small intestine of IRS-1-/-/Min versus IRS-1+/+/Min, but adenoma size did not differ 
between IRS-1+/- and IRS-1+/+ mice.  Partial and absolute IRS-1 deficiency significantly 
decreased tumor load (number x size) in both small intestine and colon (Figure 3).  
Hematocrit is considered a useful indirect measure of tumor load in ApcMin/+ mice (144, 209).  
Hematocrit was reduced in IRS-1+/+/Min and IRS-1+/-/Min mice compared to mice without 
the ApcMin/+ mutation (Figure 4).  In IRS-1-/-/Min mice, hematocrit was near normal and 
significantly higher than in IRS-1+/+/Min mice. 
β-catenin accumulation is a hallmark of adenomas in ApcMin/+ mice because loss of 
the second wildtype Apc allele leads to aberrant accumulation of β-catenin in the cytosol and 
nucleus.  β-catenin immunostaining revealed that β-catenin was localized to the intercellular 
junctions of normal crypts as previously reported (163) (Figure 5).  Tumor staining revealed 
accumulation of β-catenin in the cytoplasm and nucleus of adenomas of all genotypes 
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(Figure 5), confirming adenomatous phenotype. 
 
Reductions in Sox9 positive cells and Sox9 expression in IRS-1 deficient mice 
Sox9 is a reported biomarker of crypt stem or progenitor cells, is a target of β-
catenin/TCF-activated transcription, and is expanded in human tumors.  We therefore 
examined whether IRS-1 deficiency in ApcMin/+ mice reduced the number of Sox9 positive 
cells or Sox9 mRNA.  As shown in Figure 6a, immunofluorescence revealed that Sox9 
expression was restricted to cells at the base of normal crypts.  In IRS-1-/-/Min crypts, we 
observed an obvious reduction in both the number and staining intensity of Sox9 positive 
cells, and cell number was quantified in Figure 6b.  Immunohistochemical Sox9 staining with 
peroxidase-labeled secondary antibodies was used to better visualize the location of Sox9 
positive cells, which were found near the base of the crypts and do not appear to colocalize 
with granular Paneth cells at the crypt base (Figure 6c).  Note the presence of Sox9 positive 
nuclei in cells lying between Paneth cells in IRS-1+/+/Min but not IRS-1-/-/Min (Figure 6c).  
This is the location of multipotent Gpr49/Lgr5 positive stem cells recently reported by the 
Clevers group (7).  Thus, loss of IRS-1 appears to reduce the numbers of Sox9 positive crypt 
stem and progenitors.  Evaluation of Sox9 mRNA in small intestine of IRS-1+/+ and IRS-1-/- 
mice with or without the ApcMin/+ mutation provided quantitative evidence that IRS-1 
deficiency leads to significant reductions in Sox9 expression (Figure 7a and 7b).   
 
Sox9 expression correlates with IRS-1 levels in cultured cells 
To examine more directly if IRS-1 regulates Sox9 expression, Sox9 levels were 
examined in IEC-6 cells after infection with empty or IRS-1 expressing adenovirus. IEC-6 
  40 
 
cells show constitutive Sox9 expression, and IRS-1 adenovirus significantly up-regulated 
Sox9 protein levels by 1.8 ± 0.1 fold (Figure 8).  
 
D.  Discussion 
 
Our studies provide novel evidence that intestinal crypt epithelial cells show gene 
dosage dependence on IRS-1 for protection from irradiation-induced apoptosis.  This finding 
is noteworthy in light of recent evidence in humans that decreased levels of crypt apoptosis 
are associated with increased risk of intestinal adenoma (110), that high but within the 
normal range insulin levels correlate with both low apoptosis and adenoma risk (85), and that 
IRS-1 polymorphisms predict colon cancer risk (187).  IRS-1+/- mice exhibit only a ~50% 
reduction in IRS-1 expression and loss of one IRS-1 allele has little or no effect on body or 
intestinal growth (145, 184).  Thus, our findings that IRS-1+/- mice show significant increases 
in irradiation-induced apoptosis, with effects most prominent in the putative stem cell region, 
indicate that even small variations in levels of endogenous IRS-1 significantly impact on 
survival of genetically-damaged stem cells.  
Survival of genetically damaged stem or progenitor cells is considered a key early 
event in the development of intestinal tumors.  Consistent with this concept, partial or 
absolute IRS-1 deficiency in mice carrying the ApcMin/+ mutation led to reduced tumor 
number relative to IRS-1+/+/ApcMin/+ mice.  The more dramatic effect of IRS-1 deficiency on 
tumor number than size suggests a predominant role of IRS-1 in initiation or survival of early 
stage tumors than rate of tumor growth.  Our demonstration that reductions in endogenous 
IRS-1 limit tumor development is significant since most evidence linking IRS-1 and cancer 
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involves overexpression systems and, with a few exceptions, largely in vitro studies.  Given 
our findings in mouse models, it could be of considerable interest to establish if the IRS-1 
polymorphism linked to colon cancer risk (187) affects IRS-1 expression levels, or if patients 
with increased adenoma risk show high IRS-1 expression.  Such studies to translate our basic 
science findings to the human population have been initiated in our laboratory.  
Tumorigenesis mediated by the ApcMin/+ mutation is initiated by loss of the second 
functional Apc allele, leading to cytosolic and nuclear accumulation of β-catenin and 
activation of β-catenin-driven oncogenes (163).  Emerging evidence based in colon cancer 
cell lines or based on overexpression of IRS-1 in mouse embryonic fibroblasts or mammary 
gland in vivo indicate that IGF/IRS-1 pathways stabilize or activate β-catenin, and that there 
may be direct interactions between IRS-1 and β-catenin (26, 35, 147).  Our findings that IRS-
1 deficiency limits β-catenin driven intestinal tumorigenesis in vivo provide, to our 
knowledge, the first evidence that endogenous IRS-1 impacts on tumor promoting activity of 
β-catenin.  Qualitatively, we noted that some intestinal adeonomas of IRS-1-/-/Min mice 
appeared to show less intense or obvious nuclear β-catenin immunostaining than in IRS-
1+/+/Min adenomas.  This provides evidence that loss of endogenous IRS-1 may limit nuclear 
accumulation of β-catenin.  Attempts to verify this by more quantitative biochemical assays 
proved problematic due to variability in total and nuclear β-catenin, even within genotypes.   
More direct evidence for effects of IRS-1 on β-catenin transcription pathways stems 
from findings that expression of Sox9, a newly recognized β-catenin/Tcf target, is reduced in 
crypts of IRS-1 deficient ApcMin/+ mice in vivo and is induced in an IEC cell line by IRS-1 
overexpression.  These findings also provide novel evidence linking IRS-1 to Sox9.  Sox9 is 
emerging as a potentially important biomarker of crypt stem or progenitor cells and belongs 
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to a family of proteins known to maintain stem cells in an undifferentiated state (12).  Recent 
studies show that inactivating the Sox9 gene at a developmental timepoint prior to enterocyte 
differentiation ablates Paneth cells and, to a lesser extent, goblet cells (9, 125).  These 
findings suggest that Sox9 may play a functional role in stem or progenitor cell potency.  
Sox9 is also highly expressed in cells within human colon adenocarcinoma (12).  Thus, our 
evidence that IRS-1 regulates Sox9 expression has important ramifications for how 
IGF/insulin signaling may regulate stem cell survival and cancer risk.  The function of Sox9 
in cancer is unknown, but one speculation is that Sox9 may mark ‘cancer-associated stem 
cells.’  Thus, our findings indicate that the link between IRS-1 regulation of Sox9 and 
genetically-damaged or cancer-associated stem cells will be an interesting avenue of future 
investigation.  Futhermore, examining if Sox9 expression correlates with apoptosis, adenoma 
risk, or alterations in insulin/IGFs and IRS-1 that predict adenoma risk in humans may 
provide new insights into the etiology of early stage intestinal cancer.  
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Figure 2.1  Irradiation-induced apoptosis in jejunal crypts of IRS-1+/+, IRS-1+/-, and 
IRS-1-/- mice.  A. Histogram shows the mean number of apoptotic cells per crypt.  a=p<0.05 
vs. IRS-1+/+. N=5 for each genotype.  B. Graph shows the percent apoptotic cells at each cell 
position along the jejunal crypt for irradiated IRS-1+/+, IRS-1+/-, and IRS-1-/- mice.  Data are 
expressed as percent apoptotic cells per total cells counted at each location among ≥40 crypts 
for 5 animals of each genotype.  The increase in apoptosis in IRS-1+/- and IRS-1-/- vs. IRS-
1+/+ is most prominent in the putative stem or progenitor cell region.  a=p<0.05 vs. IRS-1+/+. 
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Figure 2.2  Representative images of adenomas in small and large intestine of ApcMin/+ 
mice.  Adenomas in small intestine (top) and colon (bottom) of ApcMin/+ mice that IRS-1+/+, 
IRS-1+/-, and IRS-1-/- genotypes are shown.  Photographs were taken at 12x under a 
dissecting scope with white light optics underneath the specimen.  Note the decrease in 
adenomas in IRS-1 deficient mice. 
 
 
 
 
 
 
 
  45 
 
 
Figure 2.3  Effects of IRS-1 gene disruption on tumors in ApcMin/+ mice.  Histograms 
show mean tumor number, size, and load in small intestine (A) and colon (B).  N=10 for 
IRS-1+/+/Min and IRS-1+/-/Min littermates, n=3 for IRS-1-/-/Min age-matched with IRS-
1+/+/Min or IRS-1+/-/Min mice.  a=p<0.05 for IRS-1+/-/Min vs. IRS-1+/+/Min littermates; b and 
c=p<0.05 for IRS-1-/-/Min vs. age-matched IRS-1+/+/Min or IRS-1+/-/Min mice, respectively. 
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Figure 2.4  Effects of IRS-1 gene disruption on hematocrit in WT or ApcMin/+ mice.  
Histogram of whole blood hematocrit from IRS-1+/+, IRS-1+/-, and IRS-1-/- mice with and 
without the Min mutation as indicated.  All hematocrit values were at or near normal range in 
mice lacking the Min mutation (32.8 - 48.0% hematocrit).  IRS-1+/+/Min and IRS-1+/-/Min 
mice had significantly decreased percent hematocrit levels, while IRS-1-/-/Min mice were 
within the normal range.  a=p<0.05 vs. all non-Min genotypes; b=p<0.05 vs. IRS-1+/+/Min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  47 
 
Figure 2.5  β-catenin immunostaining of adenomas and normal mucosa.  A. Images 
show small intestinal adenomas (10x and 40x magnification) in IRS-1+/+/Min, IRS-1+/-/Min, 
and IRS-1-/-/Min small intestine.  Note the accumulated nuclear and cytoplasmic β-catenin in 
adenomas from all three genotypes.  B. In contrast, the normal mucosa (20x magnification) 
shows prominent localization of β-catenin specifically at the lateral membrane. 
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Figure 2.6  Decreased Sox9 expression with IRS-1 deficiency.  A. Confocal images 
showing Sox9, 4’,6-diamino-2-phenylindole (DAPI), and merged immunofluorescence in 
IRS-1+/+/Min and IRS-1-/-/Min small intestine (40x).  Representative images are from 2 
animals per genotype. B. Histogram shows the mean number of Sox9 positively stained cells 
for each side of the crypt in IRS-1+/+/Min vs. IRS-1-/-/Min jejunum.  a=p<0.05 vs. IRS-
1+/+/Min.  C. Sox9 immunohistochemistry of crypts (60x), showing that cells with obvious 
Sox9 positive nuclei appear distinct from the Paneth cells.  Note the nuclear Sox9 in cells 
intercalating between the Paneth cells in IRS-1+/+/Min, but not IRS-1-/-/Min. 
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Figure 2.7  Sox9 mRNA expression.  A. Representative northern blot of Sox9 and 18S 
RNAs in ileum of IRS-1+/+, IRS-1+/-, and IRS-1-/- with and without the ApcMin/+ mutation.  B. 
Histograms show mean relative abundance of Sox9 mRNA normalized to the 18S loading 
control.  a=p<0.05 IRS-1-/- vs. IRS-1+/+ mice.  n≥4 for each genotype. 
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Figure 2.8  Sox9 protein levels are regulated by IRS-1 and IGF-I.  A. Western 
immunoblot for Sox9 or β-actin in IEC-6 cells infected with empty virus (E) or IRS-1 
adenovirus.  B. Histogram shows Sox9 protein abundance for empty vs. IRS-1 infected IEC-
6 cells normalized to actin levels.  a=p<0.05 vs. empty control, n=6 for each adenovirus. 
 
 
 
 
  
 
CHAPTER III 
 
HAPLOTYPE INSUFFICIENCY FOR SOCS2 ENHANCES GROWTH AND 
PROMOTES POLYP FORMATION IN INTESTINE OF GH-TRANSGENIC MICE 
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A.  Introduction 
 
  Even though growth hormone (GH) is FDA approved as treatment for patients with 
short bowel syndrome, the ability of exogenous GH to promote adaptive growth of the 
intestine is controversial (135, 174).  Several studies in patients with short-bowel syndrome 
(SBS) treated with GH have reported variable results (175, 177, 178).  In animal studies, 
enterotrophic actions of exogenous GH in intestine have primarily been observed in GH 
deficient models such as hypophysectomized rats infused with GH (192, 230). or in models 
of GH excess such as GH transgenic mice (GH-TG) (200).  Studies in intact rats receiving 
total parenteral nutrition (TPN) identified postreceptor resistance to exogenous GH in the 
jejunal mucosa (32).  In TPN-fed rats, GH was shown to induce expression of suppressor of 
cytokine signaling-2 (SOCS2) in intestine, and SOCS2 mRNA levels negatively correlated 
with intestinal mass (121).  In vitro studies demonstrated that SOCS2 overexpression inhibits 
proliferation of intestinal epithelial cell lines (121).  The current studies aimed to directly 
assess if SOCS2 normally limits the trophic actions of GH on intestine in vivo.  Mice with 
germ-line transmission of a mouse metallothionein-driven bovine GH gene (113). which we 
have previously characterized for small intestinal growth (200). were crossbred with mice 
heterozygous for targeted disruption of the SOCS2 allele (118) (118).  Our aim was to test 
the effects of SOCS2 deficiency on GH-transgene mediated growth of small intestine or 
colon.  Since SOCS2 was shown previously to induce sucrase expression in Caco2 cells 
(121), we also examined sucrase mRNA to assess if SOCS2 deficiency affected sucrase 
expression in vivo.    
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SOCS2 belongs to a family of eight structurally-related proteins, SOCS-1 to -7 and 
CIS (cytokine inducible SH2-domain containing protein).  These proteins contain an N-
terminal region of variable length and amino acid composition, a central SH2 domain, and a 
conserved 40 amino acid motif on the C-terminus referred to as the SOCS box (96).  SOCS 
are induced by cytokines and bind cytokine receptors or JAK kinases, acting as negative 
feedback inhibitors to limit cytokine action (60).  One mechanism of SOCS action is to limit 
the duration or magnitude of cytokine-dependent STAT activation (60).  In addition, the 
SOCS box motif interacts with elongins B and C, which are members of the proteasome-
degradation complex (233) and SOCS may therefore limit the duration of cytokine signaling 
by targeting activated signaling complexes for proteolytic degradation (60, 233).  The 
phenotype of SOCS2 null mice indicated a particular role of SOCS2 to limit the trophic 
actions of GH.  Mice homozygous for SOCS2 gene disruption are 1.3 to 1.5 times the size of 
their SOCS2+/+ littermates (118).  The increase in weight becomes evident around 42 days of 
age, a time slightly later than the onset of a body overgrowth phenotype observed in GH-TG 
mice (113, 118, 200).  The increase in body weight in SOCS2 null mice is associated with an 
increase in long bone length and a proportionate increase in the size of several organs (118).  
SOCS2 null mice have normal circulating levels of IGF-I but show characteristics of 
deregulated GH action, including increased local IGF-I production in some but not all organs 
studied (118).  SOCS2 null mice also show decreased production of major GH-regulated 
urinary protein in liver, and increased collagen deposition in the dermis (118).  Recent 
studies demonstrated enhanced body and organ growth responses to exogenous GH in GH-
deficient SOCS2 null mice, providing direct evidence that SOCS2 limits GH action in vivo 
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(61).  The effect of SOCS2 on GH-induced intestinal growth has, however, not been 
analyzed previously.   
Identifying novel mechanisms that limit the trophic effects of GH or its downstream 
effector IGF-I in the intestine is of interest, because considerable evidence implicates these 
factors in intestinal neoplasia (57).  Patients with acromegaly, due to GH secreting pituitary 
adenomas, have dramatically increased circulating levels of GH and IGF-I (50) and have 
increased risk of developing precancerous polyps and colorectal cancer compared to normal 
individuals (158, 193, 208).  The GH-TG mice used in these studies are a mouse model of 
acromegaly (94, 138).  SOCS2 gene silencing by hypermethylation is found in various cancer 
types (52, 108, 190, 214). indicating that SOCS2 may function as an endogenous inhibitor of 
the tumor-promoting actions of GH.  The present study therefore assessed the effect of partial 
deletion of SOCS2 on growth of small intestine and colon and examined the intestine for 
abnormal lesions and signs of dysplasia.  Results from these studies demonstrate that 
haplotype insufficiency for SOCS2, associated with only a 40% reduction in normal SOCS2 
expression levels, enhances the trophic actions of GH in small intestine.  SOCS2 deficiency 
also promotes the development of lymphoid and hyperplastic polyps in colon, and adenomas 
in the duodenum of GH-TG mice.   
 
B.  Materials and methods  
 
Animal Care and Genotyping 
 Derivation of mice with targeted disruption of one or both SOCS2 alleles was 
previously described (118).  Mice homozygous for SOCS2 gene disruption (SOCS2 null 
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mice) on a C57BL/6 background were provided by Drs. Douglas Hilton and Christopher 
Greenhalgh (Walter and Eliza Hall Institute of Medical Research, Victoria, Australia) (118).  
Derivation of transgenic mice (GH-TG) that constitutively overexpress a bovine GH-
transgene comprising the entire bovine GH gene linked to a mouse metallothionein 1 
promoter, was previously described (113).  Hemizygous GH-TG  mice on a C57BL/SJL 
background were originally provided by Drs. Richard Palmiter (University of Washington, 
Seattle WA) and Ralph Brinster (University of Pennsylvania Veterinary School, 
Philadelphia, PA) (113).  Mice homozygous for SOCS2 gene disruption (SOCS2-/-) and GH-
TG mice were crossbred to generate SOCS2-HT/GH-TG (SOCS2+/-/TG) and SOCS2-
HT/WT (SOCS2+/-/WT).  A second round of crossbreeding  (SOCS2+/-/TG x SOCS2+/-/WT) 
aimed to generate transgenic (TG) and wild-type (WT) mice with 0 (SOCS2-/-/WT and 
SOCS2-/-/TG), 1 (SOCS2+/-/WT and SOCS2+/-/TG) or 2 (SOCS2+/+/WT and SOCS2+/+/TG) 
functional SOCS2 alleles.  Genotyping for the WT or disrupted SOCS2 allele was performed 
on tail DNA by PCR with primers specific for the WT SOCS2 gene (sense: 5’-
CGAGCTCAGTCAAACAGGTAGG-3’; antisense: 5’-
GCTTTCAGATGTAGGGTGCTTCC-3’) or for β-galactosidase present in the disrupted 
allele (sense: 5’- GCAGACGATGGTCAGGATATCC-3’; antisense: 5’- 
GGATCGACAGATTTGATCCAGC-3’).  Genotyping for the presence of the GH-transgene 
was performed using primers specific for the bovine GH-transgene (sense: 
5’TTGACACAAACATGCGCAGT-3’; antisense: 5’GCACTTCATGACCCTCAGGTAC-
3’).  All animal protocols were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill.  
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Body and intestine growth 
  Adult female mice (100-120 days) were studied to assess the effects of partial 
SOCS2 deficiency on body and intestinal growth.  We focused on females because cross-
breeding of SOCS2 null and GH-TG mice yielded greater numbers of female littermate pairs 
with appropriate genotypes for comparisons, and male SOCS2+/-/TG mice were used for 
breeding purposes. Body weights were monitored weekly starting at day 21 (weaning).  A 
subcutaneous injection of BrdU (200mg/kg, Sigma Diagnostic Inc, St. Louis, MO) was 
administered 90 minutes prior to sacrifice.  At sacrifice, mice were anesthetized with sodium 
pentobarbital (200µg/g, Abbot Laboratories, Chicago, IL) and entire small intestine and 
colon were removed and wet weight and length assessed.  Corresponding segments of 
jejunum were quick frozen in liquid nitrogen and stored at –80°C for future analyses.  Distal 
segments of jejunum (0.5cm) were fixed in 4% formalin and paraffin-embedded for 
morphometric measurements.  Whole colon was placed on filter paper for support and 
opened longitudinally prior to fixing in 4% formalin.  Fixed colon was later analyzed under a 
Leica MZ 16 FA dissecting scope by a single observer blinded to the genotype of the samples 
to screen for and quantify abnormal lesions.  Colon was later paraffin embedded in ‘swiss-
roll fashion’ for further histological examination.  Since benign polyps were found in the 
colon of 100-120 day old mice, follow-up studies were performed on older mice (200-350 
days of age) to establish if the colon polyps increased in number, progressed to precancerous 
or cancerous lesions, or if lesions developed in small intestine.  In the follow-up studies, 
small intestine and colon were collected, fixed, and examined under a dissecting scope to 
visualize and quantify abnormal lesions. 
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Small intestine mass; villus height and crypt depth 
Frozen jejunum segments were thawed on ice and a longitudinal cut was made along 
the entire segment.  The segments were gently opened and scraped with a cold microscope 
slide resulting in a mucosal fraction and a submucosal/muscularis fraction (216).  The wet 
weight of the mucosal fraction per unit length of jejunum was measured to assess the effects 
of partial SOCS2 deficiency on mucosal mass (mg/cm). 
Paraffin embedded samples of jejunum were sectioned at a thickness of 4 µm, placed 
on positively charged slides and stained with hemotoxylin and eosin (H&E).  Crypt depth 
and villus height were measured in stained sections of jejunum by a single blinded observer.  
Measurements were performed using light microscopy and computer assisted morphometry 
as described by Williams et al., 2002 (216).  Six to ten well-oriented villi and a similar 
number of crypts were measured per segment.   
 
RNA Extraction and Northern Blot Analysis    
Total RNA was isolated from jejunum by the guanidine thiocyanate-cesium chloride 
method.  Abundance of SOCS2, IGF-I and sucrase-isomaltase mRNAs was assayed by 
northern blot hybridization using [32P]-labeled antisense cRNA or cDNA probes and methods 
detailed previously (171).  The mouse SOCS2 probe was provided by Dr. Douglas Hilton 
(Walter and Eliza Hall Institute, Melbourne, Australia), and the sucrase-isomaltase probe was 
provided by Dr. Susan Henning (Baylor University, TX).  Blots were re-probed for the 
constitutively expressed GAPDH mRNA (Ambion, Austin, TX) to control for RNA loading.  
Blots were scanned on a phosphorimager and abundance of specific mRNAs was quantified 
using Image Quant software for Macintosh. Abundance of each mRNA examined was 
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normalized to the abundance of GAPDH mRNA.     
 
Plasma IGF-I analysis 
 Plasma IGF-I levels were analyzed using the DSL-10-2900 ACTIVE mouse/rat IGF-I 
enzyme immunoassay (EIA) kit (Diagnostic Systems Laboratories, Inc., Webster, TX) 
following the manufacturer’s instructions.  Prior to assay, all samples were acid-ethanol 
extracted to remove IGF binding proteins (IGFBPs).    
 
Immunohistochemistry  
Crypt proliferation was assessed by immunohistochemistry (IHC) using a BrdU 
immunostaining kit (Zymed BrdU Staining Kit, San Francisco, CA) to label cells in S phase 
of the cell cycle based on incorporation of BrdU into DNA.  Coded sections were scored 
under a light microscope to assess the number of BrdU-positive cells per crypt. Number of 
cells per crypt were counted so that data could be expressed as the fraction of total cells per 
crypt labeled with BrdU.   
 
Colon histology and immunostaining 
Examination of the colon revealed polypoid lesions in colon of SOCS2+/-/TG and, to 
a lesser extent, SOCS2+/+/TG mice.  Swissroll embedded sections were therefore examined 
to assess histology.  Histology revealed lymphoid polyps in colon of SOCS2+/-/TG mice.  
IHC was therefore performed to assess the immune cell types present within the lesions.  
Formalin-fixed, paraffin-embedded colon was sectioned (4 µm) and placed on positively 
charged slides.  Analysis for the presence of specific lymphocyte markers used the following 
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antibodies, CD45R/B220 (B cell marker, BD Biosciences, San Jose, CA) and MAC-3 
(macrophage marker, BD Biosciences, San Jose, CA) and CD-3 (T cell marker, Dako, 
Carpinteria, CA).  In brief, sections were deparaffinized in xylene, rehydrated in graded 
ethanols (95% 4 min, 70% 3 min) to distilled water and rinsed in 0.05M Tris buffer (pH 7.6).  
This was followed by methanol, hydrogen peroxide block (30% hydrogen peroxide 1:10 
methanol, 10 min) and a rinse in water and Tris buffer (0.05M TRIS buffer, pH 7.6, 3min).  
Blocking was then performed with 2% fish gelatin (Sigma, St. Louis, MO) in Tris prior to 
incubation with primary antibody (1:25 in 2% Fish Gelatin/Tris buffer, overnight, humid 
chamber, 4ºC for 18-24 hours).  The following day, sections were washed in Tris (3x2 min) 
and incubated in secondary antibody (biotinylated mouse anti-rat IgG 1/2α, BD Biosciences, 
San Jose, CA, 1:100, room temperature, 90 min).  Slides were incubated in avidin-biotin 
complex (Vectastain, Burlingame, CA) for 75 min and labeling visualized using DAB.  β-
catenin staining of tumors was performed to determine if tumors exhibited cytoplasmic or 
nuclear β-catenin, a hallmark of early-stage precancerous lesions in mouse and human.  β-
catenin staining was performed as described in Chapter 2, using a mouse primary antibody 
(610154, BD Transduction Laboratories, Franklin Lakes, NJ) and a mouse-on-mouse 
blocking kit (BMK-2202, Vector Laboratories, Burlingame, CA).  Slides were counterstained 
in hematoxylin, dehydrated in ethanol, coverslipped and analyzed with a light microscope.   
 
Effects of SOCS2 deletion on STAT5 activation by GH ex vivo 
 Corresponding segments of small intestine (~8 cm) were isolated from SOCS2 null 
and WT mice.  The segments were flushed with 1X PBS to remove luminal contents.  One 
cm segments were incubated at room temperature with serum-free medium with or without 
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GH (10-7 M).  After 30 - 90 minutes at room temperature, segments were dounce-
homogenized in 1 ml ice-cold 1X TBS for nuclear protein extraction.  Nuclei and nuclear 
proteins were extracted using standard methods (188).  Electromobility shift assays (EMSA) 
were performed as previously described (188) on 30 µg of protein using double-stranded 
oligomers corresponding to a consensus STAT5 binding sequence (Santa Cruz 
Biotechnology, Santa Cruz, CA). 
 
Statistical Analysis 
Values are expressed as mean ± standard error of the mean (SEM).  Absolute values 
were analyzed by two-way analysis of variance (ANOVA) to test for main effects of the GH 
transgene, or SOCS2 gene disruption or an interaction between GH transgene and SOCS2 
gene disruption.  Pair-wise comparisons were performed using Tukey’s test.  Statistical 
significance was set at p<0.05.  
  
C.  Results 
 
Effects of partial SOCS2 deletion on body growth 
 Theoretically, crossbreeding of SOCS2+/-/TG and SOCS2+/-/WT should yield 
transgenic (TG) and wild-type (WT) mice with 0 (SOCS2-/-/WT and SOCS2-/-/TG), 1 
(SOCS2+/-/WT and SOCS2+/-/TG) or 2 (SOCS2+/+/WT and SOCS2+/+/TG) functional 
SOCS2 alleles.  Surprisingly, no SOCS2-/-/mice that were also GH-TG were obtained over 
the duration of the initial intestinal growth study.  To date, only one SOCS2-/-/mouse that is 
also GH-TG has been generated.  The cross did, however, generate appropriate numbers of 
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SOCS2+/-/and SOCS2+/+/ mice that were GH-TG.  Since partial SOCS2 deficiency represents 
what may be considered small and more physiological reductions in SOCS2 expression, our 
analyses focused on SOCS2+/+/WT, SOCS2+/+/TG, SOCS2+/-/WT and SOCS2+/-/TG to 
assess if haplotype insufficiency for SOCS2 altered intestinal growth induced by the GH-
transgene.  Figure 1 shows growth curves for SOCS2+/+/WT, SOCS2+/-/WT, SOCS2+/+/TG 
and SOCS2+/-/TG based on body weights measured weekly from day 21.  Consistent with 
previous reports (118). mice with one disrupted SOCS2 allele but otherwise WT (SOCS2+/-
/WT), showed no significant increase in body weight compared with their WT littermates 
(SOCS2+/+/WT).   Consistent with prior reports, SOCS2+/+ mice expressing the GH transgene 
showed an increase in body weight relative to SOCS2+/+/WT, which was apparent 
immediately after weaning (21-28 days) and then continued to be significantly larger than 
SOCS2+/+/WT littermates throughout the entire study period.  GH-TG mice lacking one copy 
of SOCS2 (SOCS2+/-/TG) did not show a significant  difference in body weight compared to 
SOCS2+/+/TG littermates at time points immediately after weaning.  The SOCS2+/-/TG mice 
did, however, demonstrate a significant increase in body weight compared to SOCS2+/+/TG 
beginning at 49 days of age and continued to be significantly larger throughout the rest of the 
study period (Figure 3.1). 
 
Loss of one copy of SOCS2 in GH-TG mice leads to increased growth in jejunum. 
 Effects of partial SOCS2 deficiency on body growth were compared with effects on 
intestinal growth.  Adult mice (100-120 days old) were studied, because prior studies had 
revealed a greater effect of SOCS2 deletion on intestinal growth in adult compared to young 
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mice.  As shown in Table 3.1, compared to their SOCS2+/+/WT littermates, adult 
SOCS2+/+/TG mice showed significant increases in body, small intestine and colon weight.  
Evaluation of SOCS2 expression revealed a significant approximately 50% reduction in 
SOCS2 mRNA in SOCS2+/-/WT and SOCS2+/-/TG compared with SOCS2+/+/WT and 
SOCS2+/+/TG (Figure 3.2).  Interestingly, neither SOCS2+/-/TG nor SOCS2+/+/TG showed 
an increase in SOCS2 expression relative to littermates lacking the GH transgene.  The 
SOCS2+/-/TG mice showed a significantly greater transgene-induced increase in body and 
small intestine wet weight compared with SOCS2+/+/TG mice having both intact SOCS2 
alleles.  Disruption of one SOCS2 allele led to a greater effect of transgene on body and 
small intestine weight compared with effects in SOCS2+/+/TG mice.  There was also a trend 
for a greater increase in colon weight in SOCS2+/-/TG vs. SOCS2+/+/TG, although this 
increase did not reach statistical significance (Table 3.1).  
 
Partial SOCS2 deficiency results in increased mucosal growth and crypt cell 
proliferation in jejunum of GH-TG mice  
 The effects of partial SOCS2 deficiency on jejunal growth were assessed, because 
prior studies demonstrated increased growth of jejunum in GH-TG (200).  Jejunal mucosal 
mass did not differ significantly in SOCS2+/+/WT and SOCS2+/-/WT but was increased in 
SOCS2+/+/TG vs. SOCS2+/+/WT mice, and an even greater increase was observed in 
SOCS2+/-/TG mice than in SOCS2+/+/TG (Figure 3.3A).  Morphometry revealed no 
significant difference in villus height and crypt depth compared with SOCS2+/+/WT mice 
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(Figures 3.3B and 3.3C).  Only the SOCS2+/-/TG mice showed a statistically significant 
increase in villus height and crypt depth in SOCS2+/-/WT compared to SOCS2+/+/WT or 
SOCS2+/-/WT (p<0.001) and these parameters were significantly greater in SOCS2+/-/TG 
than SOCS2+/+/TG (p<0.001) (Figures 3.3B and 3.3C).    
 Previous studies in adult GH-TG mice did not identify a difference in crypt cell 
mitoses compared to WT littermates (200).  Consistent with these results no significant 
change in percentage of BrdU positive cells per crypt were observed in SOCS2+/+/TG mice 
compared to their SOCS2+/+/WT littermates.  Disruption of one SOCS2 allele in GH-TG 
mice caused a small but significant increase in BrdU labeling, indicating that SOCS2 
normally limits the proliferative effects of GH on intestinal epithelial cells (Figure 3.4).  
 
Increased local but not circulating IGF-I in GH-transgenic mice lacking one copy of 
SOCS2 
To determine if more pronounced GH-transgene induced increases in jejunal growth 
in SOCS2+/-/TG vs. SOCS2+/+/TG mice were associated with an increase in circulating or 
locally expressed IGF-I, plasma IGF-I levels and jejunal IGF-I mRNAs were measured.  As 
shown in Figure 5A, the SOCS2+/-/WT mice showed no significant difference in plasma IGF-
I compared with SOCS2+/+/WT mice.  The SOCS2+/+/TG mice showed the predicted 
increase in plasma IGF-I compared with SOCS2+/+/WT mice.  The SOCS2+/-/TG mice 
showed virtually identical plasma IGF-I levels as SOCS2+/+/TG mice, indicating that 
enhanced jejunal growth was not associated with more pronounced increases in plasma IGF-I 
(Figure 3.5A).  Figure 3.5B shows data on local levels of IGF-I mRNA expression in 
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jejunum.  Jejunal IGF-I mRNA levels did not differ significantly between SOCS2+/+/WT, 
SOCS2+/-/WT or SOCS2+/+/TG.  However, SOCS2+/-/TG mice showed a significant increase 
in local IGF-I expression (Figure 3.5B).  These results indicate that the increased trophic 
effects observed in intestine of SOCS2+/-/TG mice could be driven at least in part by an 
increase in locally expressed IGF-I, which would be expected to exert paracrine effects on 
growth.  
 
Decreased sucrase-isomaltase expression in jejunum of GH-TG mice lacking one copy 
of SOCS2 
 Previous studies in Caco-2 cells have shown that SOCS2 overexpression results in 
increased sucrase-isomaltase expression and alkaline phosphatase activity (121). suggesting 
that SOCS2 may promote enterocyte differentiation.  To determine the effects of partial 
SOCS2 deficiency on differentiation, sucrase-isomaltase mRNA was measured in jejunum. 
SOCS2+/-/WT mice showed no significant change in sucrase mRNA expression compared to 
SOCS2+/+/WT, indicating that reduced SOCS2 expression alone has no effect on expression 
of this differentiation marker in the intestine of WT mice.  While SOCS2+/+/TG sucrase 
mRNA levels were not significantly different from SOCS2+/+/WT, SOCS2+/-/TG mice had 
significantly decreased sucrase-isomaltase mRNA expression (Figure 3.6).  These results 
suggest that reduced SOCS2 expression in conjunction with GH excess results in diminished 
expression of a key marker of enterocyte differentiation.     
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Formation of aberrant lesions in colon of GH-TG mice lacking one copy of SOCS2 
 Acromegaly is associated with an increased risk of colorectal cancer (158, 193).  
Because the GH-TG mice used in these studies are a model of acromegaly, the colon was 
analyzed for the presence of aberrant lesions.  No significant lesions were observed in 
SOCS2+/+/WT and SOCS2+/-/WT mice.  A small number of possible aberrant lesions were 
identified under the dissecting microscope in colon of SOCS2+/+/TG mice but could not be 
histologically-verified as polyps.  The colon of SOCS2+/-/TG mice contained a large number 
of polyp-like lesions, which were primarily localized to the proximal colon (Figure 3.7).   
 Further histological examination demonstrated the presence of lymphoid polyps as 
well as increased presence of hyperplastic mucosa or hyperplastic polyps in colon of 
SOCS2+/-/TG mice.  To better characterize the lymphoid aggregates, immunohistochemistry 
was performed using specific markers for T cells (CD-3), B cells (CD-45R/B220) and 
macrophages (MAC-3) were performed.  The lymphoid aggregates showed no significant 
staining for Mac-3 or CD-3 (data not shown), while there was intense staining for 
CD45R/B220, indicating that these aggregates are composed primarily of B cells (Figure 
3.8).  Lymphoid polyps also stained positively for BrdU, indicating ongoing B cell 
proliferation.  Increased BrdU was also consistently observed in hyperplastic mucosa 
adjacent to polypoid lesions as shown in examples in Figure 3.8.  
 
Increased STAT5 activation by GH in intestine of SOCS2 null mice 
 The effect of SOCS2 deficiency on GH signaling was addressed in small intestine of 
SOCS2 null and WT mice treated with exogenous GH.  Activation of STAT5, a major 
downstream mediator of GH signaling that has been linked to leukemia (22). was assessed by 
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EMSA.  In response to GH treatment, the intestine of SOCS2 null mice showed enhanced 
binding of nuclear proteins to a STAT5 DNA binding sequence compared with WT control 
(Figure 3.9).   
 
Effects of aging on the development of aberrant lesions in small intestine and colon 
 Older, 200 day old SOCS2+/+/TG, SOCS2+/-/TG, and one SOCS2-/-/TG mouse born 
across all litters were examined for aberrant lesions in the colon and small intestine.  In 
colon, we found that polyps did not progress to a precancerous phenotype and with age, the 
difference in polyp number between SOCS2+/+/TG and SOCS2+/-/TG was attenuated (Figure 
3.10).  One SOCS2-/-/TG had a large number of colonic polyps.  Interestingly, in aged but not 
younger mice, we observed duodenal lesions.  Histology confirmed adenomatous polyps in 
SOCS2+/-/TG, and the one SOCS2-/-/TG animal had a duodenal adenocarcinoma (Figure 
3.11).  β-catenin staining revealed largely membrane-associated β-catenin in duodenal 
adenomas but obvious nuclear β-catenin in the duodenal adenocarcinoma. 
 
D.  Discussion 
 
 These studies identified a novel effect of haplotype insufficiency for SOCS2 in 
enhancing the actions of excess GH in the intestine.  The results from these studies are 
relevant because GH is used in an increasing number of children to correct growth delay 
(102, 116) and is also used clinically in patients with long-term TPN due to SBS (40).  
Results from the current studies suggest that the intestinal response to GH therapy may be 
affected by even small changes in the levels of expressed SOCS2.
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 In this study, we aimed to examine the effects of disruption of one or both SOCS2 
alleles on GH-transgene dependent intestinal growth, because the GH transgenic mice 
represent a model of acromegaly, and we were interested in whether SOCS2 status impacts 
on normal or aberrant intestinal growth resulting from GH excess.  Other than a single 
animal, we were unable to generate multiple GH-TG mice homozygous for SOCS2 gene 
disruption.  This suggests that homozygous deletion of both SOCS2 genes and expression of 
the GH-TG is incompatible with embryonic survival.  This was unexpected because the 
phenotypes of both the SOCS2 null and the GH-TG mice do not become evident until post-
weaning.  When SOCS2 null mice were crossed with GH-transgenics overexpressing an 
ovine transgene, this also did not yield mice both homozygous for SOCS2 gene disruption 
and positive for the transgene (Greenhalgh, personal communication).  The mechanism by 
which the GH-TG compromises survival of SOCS2 null embryos is unknown.  Although 
body and organ phenotypes have been studied in GH-TG post-natally, there is no information 
about prenatal effects of GH-TG expression.  However, recent studies suggest that both GH 
and SOCS2 play important roles in neurogenesis during development of  the embryonic brain 
(157, 197).  It may be that the transgene-derived growth hormone affects embryonic brain 
development and, when combined with SOCS2 deficiency, has detrimental effects on the 
development of the central nervous system and compromises viability. This is speculative at 
present and will require further analysis.  Nonetheless, the fact that combined GH 
overexpression and absolute SOCS2 deficiency appears compromise embryonic viability 
provides new, albeit preliminary and indirect, evidence that there may be interactions 
between GH and SOCS2 during embryonic development.   
Studies in WT or GH-TG mice lacking one copy of the SOCS2 gene revealed 
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significant effects of modest (40%) reductions in SOCS2 expression on body growth and 
intestinal responses to GH excess.  This supports a concept that small and what may be 
considered physiological variations in SOCS2 expression may profoundly impact the effects 
of GH on body or intestinal growth in clinical settings of GH therapy or situations of GH 
excess such as acromegaly.  It is noteworthy that dual roles of SOCS2 as both an inhibitor 
and enhancer of GH action have been suggested. The potential enhancer role was based on 
small increases in body weight and weight of some organs in mice with widespread 
expression of supraphysiological levels of SOCS2 due to a ubiquitin promoter-driven SOCS2 
transgene, and findings that over-expressed SOCS2 bound to the GH receptor (59).  Potential 
mechanisms suggested for these effects of SOCS2 overexpression were that 
supraphysiological levels of ectopically expressed SOCS2 may have a dominant negative 
effect to perturb the actions of endogenous SOCS2, or that over-expressed SOCS2 may 
perturb the actions of other SOCS family members that normally repress GH action (59). 
Since intestine was not examined in the mice that over-express SOCS2, it could be of interest 
to generate cross-breeds of the GH-TG and SOCS2 overexpressing mice to assess how high 
levels of SOCS2 impact on phenotypic effects of GH excess in the intestine. However, the 
current studies demonstrating that small reductions in SOCS2 expression in SOCS2-HT 
enhance GH action strengthen the argument that endogenous SOCS2 generally serves as a 
negative modulator of GH action in the intestine.  
 In small intestine, disruption of one SOCS2 allele alone had no significant effect on 
growth or markers of differentiation.  However, haplotype insufficiency for SOCS2 
amplified the trophic effects of excess GH on jejunal mucosa based on major increases in 
jejunal mass, crypt depth and villus height.  The enhanced trophic effect of GH was also 
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associated with decreased expression of sucrase-isomaltase, a marker of terminal 
differentiation of enterocytes.  Thus partial SOCS2 deficiency appears to favor a less mature 
epithelium.  These results are consistent with previous observations in Caco-2 cells where 
SOCS2 overexpression resulted in increased sucrase-isomaltase expression and alkaline 
phosphatase activity (121).  It is unlikely that SOCS2 is essential for enterocyte 
differentiation since the SOCS2 null mice do not display the dramatic phenotypes of 
impaired enterocyte differentiation observed in mice with deletion in other genes such as 
Cdx-2 (10).  Nonetheless, our prior in vitro findings and the current in vivo findings indicate 
that signaling pathways regulated by SOCS2 may interact with transcription pathways 
mediating sucrase-isomaltase expression.  In this regard it is of interest to note that the 
sucrase-isomaltase gene contains several potential STAT binding sites upstream of Cdx-2 
binding sites known to induce sucrase expression (121). 
Partial SOCS2 deficiency in GH-TG mice resulted in increased crypt cell 
proliferation and increased local IGF-I mRNA expression in jejunum.  Because IGF-I has 
well-established mitogenic effects on intestinal epithelial cells (137). the increase in crypt 
proliferation may be mediated by the increase in locally expressed IGF-I.  This is also 
supported by findings from our lab that an IGF transgene targeted to mesenchymal cells had 
paracrine effects to increase growth of small intestinal epithelium (216).  The increased local 
IGF-I expression or trophic effects of the GH-transgene observed in the intestine of 
SOCS2+/-/TG mice also may be due to enhanced activation of early downstream mediators of 
GHR signaling known to be negatively regulated by SOCS2.  A likely candidate is increased 
activation of signal-transducer and activator of transcription-5b (STAT5b).  The growth 
phenotype observed in the SOCS2 null mice has been shown to require STAT5b (59).  
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STAT5b has also been shown to be essential for GH-induced IGF-I gene expression in liver 
(34).  Consistent with these prior observations, we observed enhanced STAT5 activation in 
intestine of SOCS2 null mice in response to short-term treatment with exogenous GH.  
 The presence of polyp-like lesions in the colon of GH-TG mice lacking one copy of 
SOCS2 provides novel evidence for a role of SOCS2 in limiting the development of aberrant 
intestinal lesions during GH excess.  Although hyperplastic polyps are not typically 
considered pre-cancerous lesions, prior studies have demonstrated increased frequency of 
hyperplastic polyps in acromegalic patients who are also more susceptible to colorectal 
cancer (111).  The presence of lymphoid polyps is also of interest because recent studies have 
demonstrated an increased incidence of mucosal lymphoid polyps in patients with colorectal 
cancer (130).  A few cases of non-Hodgkin’s lymphoma have been reported in patients with 
acromegaly (2).  The lymphoid polyps observed in the SOCS2+/-/TG colon were primarily 
composed of B cells.  One study reported that induction of SOCS2 in B cell lymphoma cells 
by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent immunosuppressor, renders these 
cells less responsive to mitogenic stimulation (17).  Further studies assessing the role of 
SOCS2 in B cell pathogenesis may therefore be of interest.  Since the mice used in these 
studies were relatively young, we went on to determine if the colonic lesions observed in 
SOCS2+/-/TG mice progress to a more neoplastic phenotype in older animals.  The colonic 
lesions looked similar regardless of age, both grossly and histologically.  However, duodenal 
adenomas were found in older mice, and the one SOCS2-/-/TG developed duodenal 
adenocarcinoma.  Our evidence that SOCS2 may promote tumorigenesis in the intestine is 
consistent with emerging evidence in tumors of other organs, for example SOCS2 expression 
has been shown to be down-regulated in pulmonary adenocarcinoma (214) and SOCS2 
  71 
 
hypermethylation has been observed in ovarian carcinoma cells and in patients with 
endometrial cancer (52, 190).  Our studies support a role for SOCS2 as a tumor suppressor 
and indicate that further analyses of the role of SOCS2 in tumor development and growth are 
warranted. 
GH is known to play an important role in post-natal growth.  This is highlighted in 
the GH-TG mice, which begin to show a significant increase in body weight compared to 
WT littermates at points immediately following weaning (200).  In the present studies, we 
show that the increase in body weight shown by these transgenic mice is further enhanced by 
small reductions in SOCS2 expression due to disruption of one SOCS2 allele.  These results 
are consistent with recent studies, which showed enhanced trophic effects of exogenous GH 
in GH-deficient mice lacking both copies of SOCS2 (61).  However, the fact that haplotype 
insufficiency for SOCS2 enhances the growth response to GH excess supports a concept that 
small variations in SOCS2 expression may impact on body and intestinal phenotype in 
acromegaly.  A novel finding of our studies is that the increase in body growth observed in 
the SOCS2+/-/TG mice did not manifest until the mice were 49 days of age.  This indicates 
that small reductions in SOCS2 play an important role in limiting the trophic actions of GH 
in adult mice, but have no effect at earlier stages in life. This is consistent with prior 
observations in SOCS2 null mice, where no significant effect on body weight was observed 
until the mice were 42-55 days of age (118).  Given the current interest in the effects of the 
GH-IGF-I axis in aging and longevity (8, 71, 189). future studies assessing the effects of 
SOCS2 on aging and longevity may be of interest.   
In conclusion, our findings in GH-TG mice with partial SOCS2 deficiency provide 
new evidence that endogenous SOCS2 normally limits intestinal growth and promotes 
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enterocyte differentiation during GH excess in adult animals and that normal SOCS2 
expression limits neoplasia in intestine during GH excess.  Together these studies provide 
new evidence that SOCS2 directly impacts on the actions of GH on intestine and suggest that 
the efficacy of GH therapy to promote intestinal growth in patients with SBS or intestinal 
abnormalities in acromegalic patients may be dependent on SOCS2 status. 
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Table 3.1  Deletion of 1 copy of SOCS2 in GH-TG mice leads to increases in both body 
and small intestine weight.  
 
Genotype Body Weight  
(g)  
    Small Int. Weight 
(g) 
Colon Weight 
(g) 
SOCS2+/+/WT 
 
22.1 ± 0.2 1.05 ± 0.02 0.24 ± 0.01 
SOCS2+/-/WT 
 
26.1 ± 1.2 1.14 ± 0.02 0.24 ± 0.01 
SOCS2+/+/TG 
 
  43.1 ± 1.3 a   1.78 ± 0.06 a   0.43 ± 0.03 a 
SOCS2+/-/TG 
 
    54.4 ± 1.8 a,b     2.33 ± 0.06 a,b   0.49 ± 0.04 a 
 
 Values are mean ± SEM.  n=7 littermate pairs; a=p<0.05 for TG vs. littermate control of the 
same SOCS2 genotype; b=p<0.05 for SOCS2+/-/TG vs. SOCS2+/+/TG. 
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Figure 3.1  Growth Curves.  Growth curves for female SOCS2+/+/WT (open triangles), 
SOCS2+/-/WT (open squares), SOCS2+/+/TG (solid triangles), SOCS2+/-/TG (solid squares).  
Mouse body weights were measured weekly and each point represents mean ± SEM; n=6-10 
per time point; * SOCS2+/+/TG and SOCS2+/-/TG differed from SOCS2+/+/WT and SOCS2+/-
/WT at all time points analyzed.  a = p<0.05 for SOCS2+/-/TG vs. SOCS2+/+/TG.   
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Figure 3.2  Reduced SOCS2 expression in jejunum of GH-TG mice lacking 1 copy of 
SOCS2. A. Representative autoradiograms of northern blots probed for SOCS2 and GAPDH 
control mRNAs in jejunum. B. Histograms show mean ± SEM of SOCS2 mRNA normalized 
to GAPDH mRNA; n = 4; a = p <0.05 vs. other genotypes.  
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Figure 3.3  Effects of partial SOCS2 deficiency on morphometric measures in jejunum 
of GH-TG mice. A. Histograms show wet mass of jejunal mucosa for SOCS2+/+/WT, 
SOCS2+/-/WT, SOCS2+/+/TG, and SOCS2+/-/TG mice. Values are means ± SEM; n=7; a= 
p<0.05 for TG vs. WT control of the same SOCS2 genotype, b=p<0.05 for SOCS2+/-/TG vs. 
SOCS2+/+/TG.  B. Representative 4X bright field images of H&E stained jejunum.  C. 
Histograms show mean ± SEM of villus height and crypt depth compared to control of same 
SOCS2 genotype; n=6-7; a=p<0.05 vs. other genotypes. 
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Figure 3.4  BrdU incorporation in jejunal crypt cells. 
A.  Representative 15X bright field microphotographs of BrdU immunostained cells in 
jejunal crypts.  B. Histograms show mean number of BrdU postive cells expressed as a 
fraction of mean number of cells per crypt total.  Values are means ± EM; n ≥ 6; a= p<0.05 
vs. other genotypes. 
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Figure 3.5  Plasma and jejunal IGF-I expression. A. Histograms show mean ± SEM of 
plasma IGF-I levels; n= 7; a= p <0.05 vs. control of same SOCS2 genotype. B. Top: 
Representative autoradiograms of northern blots probed for IGF-I and GAPDH mRNAs in 
jejunum. Bottom: Histograms show mean ± SEM of IGF-I mRNA normalized to GAPDH 
mRNA; n=6; a=p <0.05 vs. other genotypes.  
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Figure 3.6  Reduced sucrase-isomaltase mRNA in GH-TG mice with partial SOCS2 
deficiency.  A. Representative autoradiograms of northern blots probed for sucrase-
isomaltase and control GAPDH mRNAs in jejunum.  B. Histograms show mean ± SEM of 
sucrase-isomaltase mRNA normalized to GAPDH mRNA; n= 6; a= p <0.05 vs. other 
genotypes. 
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Figure 3.7  Formation of colonic polyp-like lesions in GH-TG mice with partial SOCS2 
deficiency. A. Representative 8X microphotographs of colon from SOCS2+/+/TG and 
SOCS2+/-/TG mice as visualized under a dissecting scope.  B. Histograms show mean 
number of polyp-like lesions present in colon.  Values are mean ± SEM; n=6-7; a= p<0.05 
vs. SOCS2+/+/TG and other genotypes. 
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Figure 3.8  Histology of colonic polyp-like lesions in HT-TG. A. Top: Representative 10X 
bright field microphotograph of H&E stained hyperplastic polyp. Middle: Serial section 
labeled with BrdU. Bottom: Immunohistochemistry shows presence of B-cells in a nearby 
lymphoid aggregate but not within the hyperplastic polyp. B. Top: Representative 10X bright 
field microphotograph of H&E stained lymphoid aggregate.  Middle: BrdU labeled serial 
section showing the presence of proliferating cells within the immune aggregate.  Bottom: 
Immunohistochemistry showing the presence of CD45R/B220 positive cells within the 
lymphoid polyp. 
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Figure 3.9  Increased STAT5 activation in intestine of SOCS2 null mice treated with 
GH. A. Representative autoradiograms of EMSA for binding of nuclear proteins to a 32[P]-
labeled STAT5 consensus sequence in small intestine of WT and SOCS2 null mice treated 
with GH or vehicle (V) for the indicated times at 0, 30, 60 and 90 min treatment with GH.  B. 
Shows STAT5-RE binding activity in positive control jejunal extracts and competition with 
excess unlabeled STAT5-RE. 
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Figure 3.10.  Colonic lymphoid polyps did not show signs of progression.  A.  
Representative images show colonic lymphoid polyps in SOCS2+/+/TG mice and in SOCS2+/-
/TG mice.  B.  Representative images of H&E (4x) staining of lymphoid polyps, showing 
similar histology to polyps found in younger mice.  C.  Dot plot shows the number of 
lymphoid polyps in SOCS2+/+/TG, SOCS2+/-/TG, and the one SOCS2-/-/TG mice, with no  
clear difference between genotypes. 
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Figure 3.11.  Duodenal neoplastic lesions in partial or absolute SOCS2 deficient mice 
expressing the GH-transgene.  A.  Representative images show duodenal adenomatous 
lesions in SOCS2+/-/TG mice and not in SOCS2+/+/TG mice.  B.  Representative images of 
H&E (4x) and β-catenin staining (10x or 20x) of duodenal neoplastic lesions.  Note little 
nuclear β-catenin staining in duodenal adenomas, while the adenocarcinoma found in the one 
SOCS2-/-/TG mouse that was generated had β-catenin positive nuclei. 
 
  
 
CHAPTER IV 
 
SOCS2 DEFICIENCY ENHANCES SPORADIC INTESTINAL TUMOR 
DEVELOPMENT, BUT HAS A LIMITED ROLE IN INFLAMMATION-MEDIATED 
INTESTINAL TUMORS 
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A.  Introduction 
 
Suppressor of Cytokine Signaling 2 (SOCS2) has been shown to inhibit the growth 
hormone/insulin-like growth factor (GH/IGF) axis.  Mice with disruption of one or both 
SOCS2 alleles exhibit a body overgrowth phenotype similar to the phenotype observed in 
GH transgenic and IGF-I transgenic mice (113, 118, 140).  By crossbreeding SOCS2-/- mice 
and mice with a point mutation in the gene encoding Growth Hormone Releasing Hormone 
(Ghrh-/-), the body overgrowth phenotype in SOCS2-/- mice was reversed (61).  Prior studies 
from our laboratory suggested that SOCS2 could limit intestinal growth induced by GH or 
GH-induced IGF-I (121).  This was based on observations that IGF-I but not GH prevented 
atrophy of the intestinal epithelium during total parenteral nutrition (TPN), and this effect 
correlated with the induction of SOCS2 by GH but not IGF-I  (121).  This was intriguing 
because GH still increased body growth and circulating IGF-I.  Since the elevated IGF-I was 
unable to elicit intestinal growth, this raised the possibility that SOCS2 limited IGF-I action 
on intestine.  The ability of SOCS2 to limit IGF-I/IGF-IR action would be quite novel, since 
this would suggest that SOCS2 may limit the actions of the IGF-IR tyrosine kinase, as well 
as its role in the action of GH.  
IGF-I has beneficial effects in cases of mucosal atrophy or bowel surgery, yet excess 
IGF-I levels can lead to colon cancer.  Circulating IGF-I levels and IGF binding proteins that 
modulate the bioavailability of IGF-I impact on risk of colon cancer in humans (56, 126, 
141).  Using liver-specific IGF-I deficient (LID) mice that have 25% the serum IGF-I levels 
of wildtype mice, it was found that the presence of IGF-I increases formation, growth, and 
metastasis of intestinal tumors (47, 223).  Therefore, factors that permit the beneficial trophic 
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actions of IGF-I while limiting its excessive activation may help prevent colon cancer.  In 
support of a role of SOCS2 in limiting IGF-I action, SOCS2 was shown to directly bind IGF-
IR and inhibit its activation, along with activation of insulin receptor substrate-1 (IRS-1), in 
the Caco2 colon carcinoma cell line (120).  IRS-1 has been linked to intestinal cancer risk in 
human epidemiology studies (187) and mouse studies (see Chapter II), suggesting that 
SOCS2 may protect against colon cancer by inhibiting IRS-1 as well.  Previous studies from 
our laboratory using IGF-I infused SOCS2-/- and SOCS2+/+ mice provided direct evidence 
that SOCS2 deficiency enhanced the proliferative, trophic, and anti-apoptotic actions of IGF-
I (120).  SOCS2 deficiency also augmented the growth-promoting actions of epidermal 
growth factor (EGF) on intestine (120), another growth factor linked to colon cancer in 
humans and mouse mutant studies (51, 115, 124, 163).  Furthermore, increased GH secretion 
in acromegaly correlates with increased risk of colorectal cancer in humans (79, 112), and 
mice with disruption of one SOCS2 allele that express a GH transgene have increased benign 
colonic lesions and duodenal adenomas (see Chapter 3).  This suggests that during GH 
excess, also associated with elevated IGF-I, reduced levels of SOCS2 may promote aberrant 
lesions in the colon.  We therefore postulate that SOCS2 may normally protect against cancer 
by inhibiting the tumorigenic actions of numerous growth factors, including GH, IGF-I, IRS-
1, and EGF. 
SOCS2 has been linked to cancer susceptibility, particularly in epigenetic studies.  A 
role of SOCS2 in tumor formation is supported by data showing that SOCS2 gene 
inactivation by hypermethylation of CpG islands within the SOCS2 promoter region 
correlates with various types of cancer, including prostate, breast, ovarian, and endometrial 
cancer (30, 49, 52, 68, 190, 203).  Other SOCS proteins have been implicated in cancerous 
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growth as well.  SOCS1 is hypermethylated in breast cancer and in glioblastoma cells (235).  
SOCS3 expression was increased in glioblastoma cells (235) and both SOCS1 and SOCS3 
were hypermethylated in Barrett’s adenocarcinoma (195).  Our laboratory recently 
demonstrated that epithelial-specific SOCS3 deletion leads to greater tumor load using the 
azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model of inflammation-induced 
intestinal cancer (162).  This indicates a role for SOCS3 in normally limiting inflammatory 
bowel disease-related colon cancer.  Thus, SOCS3 may have a particular role in protecting 
against intestinal tumors during inflammation.  Despite the evidence that SOCS3 limits 
inflammation-mediated colon cancer and correlations between SOCS2 levels and colon 
cancer, the role of SOCS2 in intestinal cancer is not defined. 
The current study tested whether SOCS2 plays a role in sporadic intestinal tumor 
formation in genetically-susceptible mice.  We crossbred SOCS2 knockout mice with the 
ApcMin/+ model of spontaneous polyposis in intestine and hypothesized that SOCS2 
deficiency would lead to greater or larger tumors in this model.  Since our laboratory has 
linked SOCS3 to inflammation-associated tumors using the AOM/DSS model, we also 
treated SOCS2-/- mice with AOM/DSS to help distinguish the role of SOCS2 in spontaneous 
versus inflammation-associated cancer.  We hypothesized that while SOCS3 deficiency 
promotes inflammation-mediated colon cancer, SOCS2 deficiency would preferentially 
affect sporadic, rather than inflammation-mediated, tumorigenesis in normal intestine.  SOCS 
proteins are negative regulators of the Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) pathway, inhibiting signaling by either inactivating JAKs or 
blocking receptor binding sites for STATs (60, 160).  STAT5b is necessary for GH-
stimulated IGF-I production, and the body overgrowth phenotype of SOCS2-/- mice is 
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dependent on STAT5b (34, 59).  We therefore postulated that SOCS2 may inhibit intestinal 
tumorigenesis through inhibition of STAT5 or its homologues STAT1 and STAT3.  This 
hypothesis is consistent with data showing that GH infusion increases STAT5 transcriptional 
binding activity in intestine, and IGF-I infusion increases STAT3 transcriptional binding 
activity in mice (119, 120).  STAT activity is linked to cancer in other organs (18) but, to our 
knowledge, STAT activation has not previously been reported in ApcMin/+ or β-catenin-
driven tumors. 
 
B.  Materials and methods 
  
Laboratory animals   
ApcMin/+ male mice were purchased from Jackson lab, and mice with targeted 
disruption of the SOCS2 gene were developed as previously described and provided by Dr. 
Christopher Greenhalgh (118).  To generate SOCS2 knockout mice on the ApcMin/+ 
background, SOCS2+/- were crossbred with ApcMin/+ mice, and SOCS2+/-/ ApcMin/+ mice 
were selected among their progeny.  SOCS2+/-/ApcMin/+ mice were bred with SOCS2+/- to 
generate ApcMin/+ mice that were SOCS2-/-, SOCS2+/- and SOCS2+/+.  Genotyping was 
performed on tail DNA using oligomers from a previous publication (119, 163).  Males and 
females across litters were studied for tumor load in the ApcMin/+ model to maximize the 
number of mice per genotype, since studies included SOCS2+/+, SOCS2+/-, and SOCS2-/-.  
All animal studies were approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina.  Study protocols were in compliance with the Guide for the 
Care and Use of Laboratory Animals published by the NIH. 
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Electromobility shift assay (EMSA) for STAT binding in ApcMin/+ tumors versus 
normal tissue 
We first compared STAT DNA binding activity in tumors versus normal tissue of 
ApcMin/+ mice to assess if STAT activation accompanied tumor development.  Segments of 
intestine were collected from small intestine and were flushed with ice-cold PBS to removed 
luminal contents.  Tumors were dissected out from remaining tissue under a dissecting scope 
and both tumor tissue and normal surrounding intestinal tissue were dounced homogenized in 
1ml ice-cold 1x Tris-buffered saline for nuclear protein extraction using methods described 
previously (188).  EMSAs were performed as established (188) using 30 µg protein using 
double-stranded oligomers corresponding to a consensus STAT1, 3, or 5 binding sequence 
(Santa Cruz Biotechnology, Santa Cruz, CA).   
 
Tumor scoring in SOCS2+/+ and SOCS2-/- mice with the ApcMin/+ mutation   
At the time of sacrifice, mice were anesthetized and blood was collected by cardiac 
puncture for hematocrit.  The small intestine was separated into 3 pieces and the colon kept 
intact.  Each intestinal region was flushed with PBS, splayed open onto 3MM Whatman 
paper and fixed in 10% formalin overnight at 4º C.  Adenoma number for small and large 
intestine of each animal was counted under a dissecting scope, using an in-lens micrometer to 
measure adenoma diameter.  Intestinal sections were rolled into a swissroll, paraffin-
embedded, and sectioned at 7µm.  The presence and morphology of adenomas were 
confirmed by H&E- and β-catenin-staining of swissrolls.  Since ApcMin/+ mice are known to 
get severe anemia as disease progresses, hematocrit was measured as an indirect marker for 
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tumor load and disease severity.   
 
Immunohistochemistry 
Dewaxed and rehydrated swissroll sections underwent epitope retrieval in 10mM 
citrate buffer and were blocked of endogenous peroxidase activity with 3% H2O2.  Νormal 
blocking serum was used from a Vectastain ABC kit (Vector laboratories, Burlingame, CA) 
or from a MOM kit for mouse antibodies (BD Transduction laboratories, #610154), followed 
by incubation with antibodies for CD3 (T cell marker; Dako, Carpinteria, CA), CD45/B220 
(B cell marker; BD Biosciences, San Jose, CA), F4/80 (macrophage marker; Abcam #6640, 
Cambridge, MA), or β-catenin (BD Transduction Laboratories, #610154, Franklin Lakes, 
NJ).  Bound antibody was detected with a Vector Elite kit (Vector laboratories, #PK-61601) 
or biotinylated anti-mouse IgG from the MOM kit, followed by DAB substrate.  Tissues were 
counterstained in hematoxylin.  Primary antibody was omitted as a negative control.  When 
possible, tissues known to highly express or lack proteins of interest were used as positive 
and negative controls, respectively.  
 
AOM/DSS treatment  
Sex- and age-matched SOCS2+/+ and SOCS2-/- pairs were given a single 
intraperitoneal (i.p.) injection of 10 mg/Kg AOM.  Seven days later, mice were administered 
2.5% DSS for 5 days (TDB Consultancy, Sweden), followed by 14 days recovery on water.  
This cycle was repeated three times, and mice were monitored for blood in their stool using a 
Hemoccult Sensa kit (Beckman Coulter, Fullerton, CA) to confirm that treated mice were 
undergoing intestinal inflammation and neoplastic growth.  Mice were sacrificed and studied 
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60 or 80 days following AOM injection. 
 
Statistical analyses   
Values for average adenoma number and size were expressed as mean ± SEM.  
Comparisons between SOCS2+/+/Min, SOCS2+/-/Min, and SOCS2-/-/Min were not confined 
to littermate or sex-matched pairs due to the heterogeneity of genotypes derived in each litter.  
Therefore, ANOVA was also used in ApcMin/+ mice to determine if there was a significant 
interaction between SOCS2 genotype and tumor number, size, or load, as well as percent 
hematocrit.  In AOM/DSS studies, ANOVA was used to determine if there was a significant 
interaction between tumor number or percent hematocrit and SOCS2 status.  P<0.05 was 
considered to be statistically significant.   
 
C.  Results 
 
Increased STAT transcription factor binding in tumor versus normal intestine 
Tissue from intestinal tumors and normal tissue of ApcMin/+ mice were compared for 
STAT1, STAT3, and STAT5 promoter binding by electromobility shift assay.  As shown in 
Figure 4.1, preliminary data suggests that tumor tissue may have enhanced binding of nuclear 
proteins to STAT1, 3, and 5 promoter binding sequences compared to normal tissue.  
Athough additional experiements are required to confirm this finding, this supports the 
concept that SOCS2, a major regulator of STAT activation, may impact on ApcMin/+ tumors. 
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Increased adenoma in SOCS2 deficient ApcMin/+ mice 
In small intestine, tumor number significantly increased by over 2-fold in SOCS2-/-
/Min and by 1.4-fold in SOCS2+/-/Min compared to SOCS2+/+/Min mice (shown in Figure 
4.2 and quantified in Figure 4.3).  Tumor number in colon increased 2.8-fold in SOCS2-/-
/Min and 1.6-fold in SOCS2+/-/Min compared to SOCS2+/+/Min.  Tumor size was not 
significantly affected in small intestine or colon.  Tumor number and size were multiplied for 
small intestine and colon to calculate tumor load, which was increased in all genotypes 
compared to SOCS2+/+/Min in both small intestine and colon.  Hematocrit was measured as a 
secondary measure of tumor load, indicating significant anemia in SOCS2-/-/Min mice, but 
not in SOCS2+/+/Min or SOCS2+/-/Min mice (Figure 4.4). 
 
ApcMin/+ tumors are not comprised of immune cells 
Adenomas in the ApcMin/+ model of both SOCS2+/+ and SOCS2-/- mice were stained 
for various immune cell markers, including CD45/B220 (B cells), CD3 (T cells), and F4/80 
(macrophages) as shown in Figure 4.5.  While Peyer’s patches stained positively for B and T 
cells as expected, ApcMin/+ tumors had little or no detectable CD45/B220 or CD3 cell 
staining, indicating neither SOCS2+/+ nor SOCS2-/- adenomas had an upregulation of B or T 
cells.   F4/80, a macrophage marker, was detected in tumors with no obvious difference 
between staining in the tumors of SOCS2+/+ and SOCS2-/- mouse intestine.  
 
No significant difference in AOM/DSS tumorigenesis in SOCS2 deficient mice 
Mice that had both SOCS2 alleles deleted (SOCS2-/-) and mice with both alleles
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intact (SOCS2+/+) mice were given AOM injections as a mutagen, followed by DSS to 
induce colitis.  All mice treated with AOM/DSS had bloody stool and grossly visible 
hyperplasia and inflammation (Figure 4.6a and b).  There was no significant difference 
between tumor number in the colon (Figure 4.7a) or whole-blood percent hematocrit (Figure 
4.7b) between SOCS2+/+ and SOCS2-/- mice.  Tumors were confirmed histologically by H&E 
and nuclear β-catenin staining, showing similar histology.   Nuclear β-catenin staining was 
observed in AOM/DSS-induced tumors in both SOCS2+/+ and SOCS2-/- mice (Figure 4.6c). 
 
D.  Discussion 
  
We explored the potential role of SOCS2 in β-catenin-mediated and inflammation-
associated intestinal tumor formation.  SOCS2 deficiency increases susceptibility to β-
catenin-mediated intestinal tumors, leading to an increase in tumor number in small intestine 
and colon.  Therefore, studies examining the effect of SOCS2 levels on β-catenin 
transcriptional targets are currently being performed in the laboratory.  Despite evidence that 
SOCS3 is involved in inflammation-associated cancer, SOCS2 deficiency did not lead to 
greater tumor load in the AOM/DSS model.  Furthermore, tumors in the ApcMin/+ mice were 
not rich in B cells or T cells, suggesting that the immune system plays little role in the 
increased tumor load with SOCS2 deficiency.  The intriguing concept that SOCS3 plays a 
role in limiting inflammation-associated cancer and SOCS2 in sporadic, β-catenin-mediated 
cancer suggests that studies of the roles of SOCS2 or SOCS3 silencing in sporadic versus 
inflammation-associated cancer in humans will be of interest. 
Since immune cell types commonly found in inflammatory tumors were not 
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upregulated in the ApcMin/+ tumors, we will explore possible mediators of SOCS2 
tumorigenic action beyond the pro-inflammatory cytokines typically linked to SOCS2 
signaling.  We hypothesize that SOCS2 deficiency may promote tumor development by 
enhancing STAT signaling.  STAT3 is constitutively expressed in colon cancer (88).  
Constitutive activation of STAT3 and STAT5 is associated with cell transformation, tumor 
formation, and growth in breast cancer, leukemia, and lymphoma tumors and cell lines (18, 
54, 123).  Furthermore, STAT5b is activated in response to GH (89), and data from our lab 
shows that GH-induced STAT5 promoter binding is enhanced in SOCS2 deficient mice 
(119).  Our preliminary studies show that STAT1, 3, and 5 promoter binding is increased in 
ApcMin/+ tumors compared to normal surrounding tissue, suggesting that STAT signaling is 
activated during tumor formation in this model.  STAT binding had not previously been 
examined in this model and such studies were needed prior to studies examining the effect of 
SOCS2 status on STAT binding activity.  We are currently testing whether SOCS2 
deficiency impacts on STAT promoter binding in tumors and normal tissue from the ApcMin/+ 
mice.  
 Additionally, IGF-I and EGF are two main tumor-promoting signaling molecules that 
are inhibited by SOCS.  SOCS2 may normally protect the intestinal epithelium against cancer 
by inhibiting IGF and/or EGF signaling.  SOCS2 deficient mice have augmented intestinal 
growth in response to both IGF-I and EGF infusion (120).  IGF-I is the main mediator of GH 
action, and we have shown that GH excess can lead to intestinal lesions in SOCS2 deficient 
mice (see Chapter 3).  We have also examined SOCS2 deficient mice expressing an IGF-I 
transgene and observed preliminary data for numerous pre-cancerous colonic lesions in this 
model similar to those in the GH transgenics discussed in Chapter 3 (data not shown).  These 
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studies were not pursued due to difficulties in breeding this mouse line and therefore sample 
size for these data are limited.  EGFR deficiency can protect against adenoma development 
in ApcMin/+ mice (163), and the EGFR has been found to be overexpressed in cancer cell lines 
(89).  SOCS2 may inhibit EGF signaling by its inhibition of GH action, since GH can 
transactivate the EGFR (227).  SOCS2 could also inhibit EGF activity by inhibiting STAT5b, 
since EGF has been linked to STAT5b activation (89).  Future studies will therefore aim at 
testing if adenomas formed in SOCS2 deficient mice have increased IGF-I expression, 
elevated IGF-IR or EGFR activation, or elevated STAT activation.  
If IGF-I, EGF, and STATs are all implicated in tumor development in SOCS2 
deficient mice, it is possible that SOCS2 may serve as an attractive therapeutic target itself, 
by simultaneously inhibiting the tumorigenic actions of all three pathways.  Cell-permeant 
(CP) forms of other SOCS have been developed and so far CP-SOCS3 has been shown to 
limit acute inflammation in liver (81).  CP-SOCS2 mimetics could therefore be developed 
and tested for therapeutic potential in intestinal cancer.  Since SOCS2 is normally produced 
in the body, SOCS2-based therapies, alone or in conjuction with lower-dose chemotherapy, 
may serve as an attractive cancer therapy in the future. 
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Figure 4.1.  Increased STAT1, 3, and 5 transcription factor binding in tumor compared 
to normal intestine.  Electromobility shift assay for STAT1, STAT3, and STAT5 binding in 
tumors compared to normal tissue from ApcMin/+ mouse small intestine.  Cold competitor (cc) 
and a positive control (+) are shown for each response element.  Total protein is shown as a 
loading control.  Note the increased STAT1, 3, and 5 binding activity in tumor compared to 
normal tissue. 
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Figure 4.2.  Representative images of adenomas in small and large intestine of ApcMin/+ 
mice.  Adenomas in small intestine (top) and colon (bottom) of ApcMin/+ that are SOCS2+/+, 
SOCS+/-, and SOCS-/- genotypes are shown.  Photographs were taken at 12.3x under a 
dissecting scope with white light optics underneath the specimen.  Note the increase in 
adenomas in SOCS2 deficient mice. 
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Figure 4.3.  Effects of SOCS2 gene disruption on tumors in ApcMin/+  mice.  Histograms  
show mean tumor number, size, and load in small intestine (a) and colon (b).  N≥9 for  
ApcMin/+ mice that were SOCS2+/+, SOCS2+/-, and SOCS2-/-.  A=p<0.05 for SOCS2-/-/Min vs.  
SOCS2+/+/Min and b=p<0.05 for SOCS2+/-/Min vs. SOCS2+/+/Min mice. 
 
  100 
 
 
Figure 4.4.  Effects of SOCS2 gene disruption on hematocrit in WT or ApcMin/+ mice.  
Histogram of whole blood hematocrit from SOCS2+/+, SOCS+/-, and SOCS-/- mice with and 
without the ApcMin/+ mutation as indicated.  All hematocrit values were at or near normal 
range in mice lacking the Min mutation as well as in SOCS2+/+/Min mice (32.8-48.0% 
hematocrit).  SOCS+/-/Min and SOCS-/-/Min mice had significantly decreased percent 
hematocrit levels.  a=p<0.05 vs. all non-Min genotypes. 
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Figure 4.5.  Immune cell staining in Peyer’s patches and adenomas.  SOCS2+/+/Min and 
SOCS-/-/Min mouse Peyer’s patches and intestinal adenomas stained for B cells with 
CD45/B220 (A), T cells with CD3 (B), and macrophages with F4/80 antibody (C) are shown 
at 10x magnification.  Note no obvious difference in staining between adenomas of 
SOCS2+/+/Min and SOCS-/-/Min mice. 
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Figure 4.6.  Gross and histological images from SOCS2+/+ and SOCS-/- mice treated with 
AOM/DSS.  Representative images show gross morphology (A), H&E (B), and β-catenin at 
4x and 40x magnification (C) in SOCS2+/+ and SOCS-/- mice treated with AOM/DSS.  Note 
no noticeable change in tumor number or morphology between SOCS2+/+ and SOCS-/- mouse 
intestine. 
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Figure 4.7.  No significant change in adenoma number and percent hematocrit in 
SOCS2+/+ compared to SOCS2-/- mice treated with AOM/DSS.   Histogram shows mean 
adenoma number (A) and percent hematocrit (B) for SOCS2+/+ compared to SOCS2-/-, with 
no significant change found. 
 
 
 
 
 
 
 
 
 
 
 
  
 
CHAPTER V 
 
GENERAL DISCUSSION 
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A.  Targeting IRS-1 in intestinal tumors 
 
Colon cancer prevalence is most dramatically increasing in developed countries, 
suggesting that environmental factors likely play a role in its development (56).  A strong 
correlation has been observed between colon cancer and obesity, a major health issue 
throughout the world (58, 63).  Obesity has reached epidemic proportions and is most 
prevalent in areas that eat a Westernized diet high in fat, processed foods, and refined grains 
(63, 179).  Therefore, numerous studies have been aimed at identifying specific dietary and 
lifestyle factors related to obesity that predispose to colon cancer, with very few studies 
providing any substantial links.  Dietary factors like fiber, meat, and fat intake have all been 
tested for their colon cancer preventative properties, with controversial results or little 
correlation between intake and disease susceptibility (164).  While the cancer promoting or 
protective effects of specific nutrients remain elusive, it has been shown that elevated insulin 
levels in obese and diabetic individuals are linked to an increased risk of colon cancer (85).  
Furthermore, high circulating levels of related peptides IGF-I and IGF-II have both been 
linked to colon cancer (210).  Insulin and IGFs all exert their growth-promoting actions 
predominantly through IRS-1.  Therefore, we conducted studies testing if IRS-1 levels could 
affect crypt apoptosis and tumor formation in mouse intestine.   
  Chapter II reports our findings that IRS-1 deficiency promotes irradiation-induced 
apoptosis of potential crypt stem or progenitor cells, a process that most likely protects 
against clonal expansion of genetically-damaged cells to neoplastic lesions (152, 155).   
Since our findings suggested a role for IRS-1 in intestinal cancer, IRS-1 deficient mice were 
crossbred with the ApcMin/+ model of intestinal polyposis.  In these studies, it was found that 
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even partial IRS-1 deficiency in mice heterozygous for IRS-1 gene disruption protects 
against β-catenin-mediated tumors.  IRS-1 deficiency also correlated with a decrease in 
protein and mRNA levels of Sox9, a potential stem cell marker known to be involved in 
colon cancer (12).   These experiments indicate that further study of IRS-1 as a biomarker of 
colon cancer risk or a therapeutic target to prevent or treat intestinal cancer would be of 
interest.  Studies exploring the use of IGF-IR tyrosine kinase inhibitors are already underway 
in numerous laboratories (73, 205, 229).  Inhibiting the IGF-IR, however, could be 
ineffective since this would not disrupt insulin signaling.  Inhibiting insulin signaling may be 
vital in cancer prevention, since high insulin levels correlate with intestinal adenoma 
formation, and insulin stimulates breast cancer cells to proliferate (85, 229).  IGF-II 
activation of the insulin receptor has also been shown in a breast cancer cell line (229).  
While potentially protective against colon cancer, inhibiting both the IGF-IR and the insulin 
receptor could have detrimental effects on glucose homeostasis (229).  By targeting IRS-1, 
the anti-apoptotic or trophic actions of IGF-I, IGF-II, and insulin (all of which are linked to 
colon cancer) could be inhibited, while leaving IRS-2 signaling intact.  This is favorable 
because available evidence indicates that trophic and anti-apoptotic effects in intestine are 
mainly mediated by IRS-1 while IRS-2 is important in maintaining glucose homeostasis and 
can compensate for the metabolic side effects of loss-of-function of IRS-1 (5). 
  
B.  IRS-1/β-catenin interactions 
 
Once we established that IRS-1 deficiency protects against intestinal adenoma in 
ApcMin/+ mice, we wanted to examine the mechanism by which IRS-1 levels modulate 
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adenoma susceptibility.  Original proposed mechanistic studies were based on potential 
interactions between IRS-1 and β-catenin.  Various studies in cell lines indicate that IRS-1 
and β-catenin are bound at the membrane, until they translocate to the nucleus upon IGF-I 
stimulation and activate various cell cycle progression genes downstream of β-catenin (26, 
147, 222).  This interaction at the membrane may play an important role in cell-cell adhesion, 
since β-catenin is part of the adherens junction, a dynamic membrane complex comprised of 
E-cadherin, α-catenin, and actin (44, 225).  Further support for a role of IRS-1 in cellular 
adhesion derives from a study in a neuroblastoma cell line showing that IRS-1 binds β1-
integrins, and IRS-1 protein degradation disrupts this interaction causing the cell to undergo 
anoikis (86).  Not only is a role for IRS-1 in adhesion likely important for cell survival and 
apoptosis, but it has been shown that adhesion and cytoskeletal components play a key role in 
tumor metastasis.  Studies show in breast cancer metastasis that epithelial cells acquire a 
more mesenchymal cell phenotype, losing E-cadherin-mediated adhesion at the membrane 
and expressing mesenchymal cell markers, termed epithelial mesenchymal transition (EMT) 
(107).  This mesenchymal-like cell type is favorable for migration into the blood stream and 
invading distant organs, where it reverts back to its original epithelial phenotype (107).  
Whether IRS-1 plays a role in cytoskeletal organization in this EMT process remains 
unknown. 
 Although in vivo IRS-1/β-catenin interactions were theoretically an interesting 
avenue to pursue, preliminary studies proved quite difficult.  In immunoprecipitation 
experiments, β-catenin was found to bind Protein A and G agarose beads in controls that had 
no IRS-1 or β-catenin antibody added.  IRS-1 is not abundant enough in intestinal tissue for 
immunostaining for colocalization studies.  IRS-1 adenovirus overexpression and siRNA 
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could be an easier potential means of studying IRS-1/β-catenin interactions, but such studies 
would simply support already published in vitro data and these less novel experiments were 
not a priority during the studies described here.  One study that could be pursued in the 
laboratory, which has not yet been performed due to a lack of IRS-1-/-/Min mice, is to 
immunoprecipitate E-cadherin in IRS-1+/+ versus IRS-1-/- mouse intestine or isolated crypt 
protein extracts and immunoblot for β-catenin.  This would help determine whether IRS-1 
levels play a major role in the stability of the adherens junction, which could be a potential 
mechanism whereby IRS-1 promotes intestinal tumor formation.  Since such studies were 
dependent on the generation of IRS-1-/-/Min mice, we went on to examine levels of Sox9 in 
our tumor model, since Sox9 is a key transcriptional target of β-catenin. 
 
C.  The intestinal stem cell 
 
Our studies described in Chapter II show that IRS-1 deficiency promotes irradiation-
induced apoptosis within the putative stem cell area, a region that is labeled by Sox9 staining.  
However, much controversy surrounds studies aimed at proving where exactly the intestinal 
stem cells reside.  Label-retaining studies or studies by Potten on susceptibility of stem cells 
to radiation have been the major method for finding potential stem cells in the past and have 
indicated that the stem cells reside around positions 3-5 in the crypt (27, 153, 155).  Quite 
recent data claim that cells that express Lgr5, a G-protein coupled receptor (Gpr49) with no 
known ligand, can give rise to all intestinal cell types in lineage-tracing studies (7).  
Lgr5/Gpr49 expression is confined to crypt base columnar cells that intercalate between 
Paneth cells (7).  This study introduced a new crypt cell numbering system, whereby the 
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bottom of the crypt is referred to as 0 and intercalating crypt base columnar cells are 
numbered 1’, 2’, and so on, depending on their position.  Comparisons of putative stem cell 
position between these and Potten’s studies are made difficult by this new numbering system 
along with the general heterogeneity of crypt architecture.  Therefore, whether Lgr5 marks 
the same cells that express Sox9 is not yet known.  In staining shown in Chapter II, it appears 
that Sox9 is expressed in crypt cell positions 3-5 and in the intercalating cells between the 
Paneth cells at the base of the crypt. 
Dr. Scott Magness, a collaborator of our laboratory, has made Sox9/eGFP mice that 
show high and low expressing Sox9/eGFP cells in the intestinal crypts.  Low Sox9/GFP cells 
are small cells at the base of the crypts, intercalated with Paneth cells, virtually identical to 
the location of Lgr5/Gpr49 ‘stem cells’ reported by Barker et al., 2007 (7).  Dr. Magness’ lab 
is currently FACS sorting the high versus low expressing cells for use in microarray studies.  
Such studies will be important to determine if certain levels of Sox9 correlate with elevated 
expression of genes associated with stem cells or commitment to particular differentiation 
pathways as well as cancer.  It is possible that low levels of Sox9 keep cells proliferative and 
undifferentiated as a stem or progenitor cell, while high levels of Sox9 promote 
differentiation of Paneth and/or goblet cells.  Experiments in the lab will compare Lgr5 and 
Sox9 expression patterns in both WT and IRS-1 deficient intestine, and the effects of IGF-I 
on survival of Lgr5 and Sox9 positive cells.  Because current data suggest that Sox9 labels a 
greater number of cells within the crypt than Lgr5, it is likely that Lgr5 labels a subset of 
Sox9 positive cells.  An exciting area to pursue in the future will be to differentiate between 
cells that express both Lgr5 and Sox9 versus only Sox9 to test if Lgr5/Sox9-positive cells 
show more stem cell and Sox9 only-positive cells show more progenitor cell characteristics.  
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Even if Lgr5 proves to be a true stem cell marker and Sox9 does not, it will still be 
imperative to determine the physiological function of Sox9 in normal intestine and in tumors, 
since it is highly expressed in proliferative crypt compartments and tumors. 
 To help elucidate if Sox9 or Lgr5 are true stem cell markers, future studies will also 
determine if Lgr5 or Sox9 expressing cells are capable of regenerating the entire crypt 
following irradiation.  When the intestine is subjected to high dose irradiation, our lab has 
observed that the majority of crypt cells are lost.  After irradiation, small foci of proliferating 
cells (microcolonies) regenerate crypts and these colonies are believed to arise from clonal 
expansion of single surviving stem cells.  Preliminary studies in our laboratory using 
Sox9/eGFP mice given high-dose irradiation indicate that microcolonies express the 
Sox9/eGFP reporter, but Lgr5 expression has not yet been examined.  Future studies will 
confirm this finding and determine whether these Sox9 positive cells are capable of reversing 
the irradiation-induced mucosal atrophy over time.  Our laboratory is currently studying the 
timecourse by which these cellular foci are formed and when the crypts begin to regenerate.  
Once the timecourse is established, our lab will examine various characteristics of the cells 
within the foci, such as Sox9, IRS-1, and Lgr5 expression levels and if IGF-I promotes 
regeneration by increasing the number of Sox9/eGFP cells or microcolonies.  Dr. Magness 
and Dr. Lund are also developing Sox4/eGFP reporter mice since Sox4 labels a more 
restricted population of cells in the crypt than Sox9 (Magness, personal communication), and 
the laboratory is also obtaining the Lgr5/LacZ reporter mouse used by Barker, et al., 2007 
(7).  These mice will be used in the future to more definitively address the role of the 
IGF/IRS-1 system in stem cell survival and in tumor-associated stem cells. 
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D.  SOCS2 as a modifier of GH action  
 
GH is an FDA-approved therapy for short bowel syndrome (SBS), a malnutrition and 
malabsorption syndrome that results from repeated or massive bowel resection.  Patients with 
SBS often require TPN feeding for extended time periods, if not for the patient’s entire 
lifetime.  GH stimulates growth of the remainder of the bowel, both in length and mucosal 
thickness of the gut, leading to improved nutrient absorption that is vital to further intestinal 
growth and repair (143).  GH is also abused in competitive sports due to its stimulatory 
actions in lean muscle mass growth.  Although GH has beneficial effects, excess levels of 
GH or its downstream mediator IGF-I are linked to increased risk of intestinal neoplasia.  
Increased GH secretion in acromegaly correlates with increased risk of colorectal cancer in 
humans (79, 112).  Therefore, understanding the mechanisms whereby GH can promote 
mucosal growth and repair during atrophy or pathological settings, while not becoming 
excessive and promoting cancerous growth, are vital.   
Studies of SOCS2 in our lab have stemmed from findings in TPN-fed rats given GH 
or IGF-I infusion.  TPN fed rats showed severe mucosal atrophy, which was almost 
completely reversed by IGF-I infusion (121, 146).  However, rats given GH infusion, in 
which circulating IGF-I levels were similar to those in IGF-I infused rats, did not show 
mucosal regrowth.  Screening for mRNA levels of the SOCS family of proteins showed that 
SOCS2 was expressed following GH treatment, but not IGF-I treatment.  These studies led to 
our later proven hypothesis that SOCS2 is a GH-inducible inhibitor of its own actions (121).  
The more potent effects of IGF-I infusion suggest that IGF-I may serve as a more effective 
therapy for SBS than GH.  However, despite promising intestinal adaptive growth effects of 
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IGF-I in animal models, IGF-I therapy has numerous unwanted side effects preventing it 
from becoming an approved therapy, including generalized edema, arthralgia, myalgia, 
hypotension, and intracranial hypertension (122, 156, 204).  GH is most likely a safer therapy 
due to its induction of SOCS2, which could provide the balance between the adaptive growth 
actions of GH while limiting excess growth that could lead to neoplasia.   
As described in Chapter III, GH transgenic expression in SOCS2+/- mice increased 
overall body size as well as numerous growth parameters in the intestinal mucosa, including 
villus height, crypt depth, increased proliferation, decreased apoptosis and decreased 
differentiation.  One potential mechanism of GH action in intestine of SOCS2 deficient mice 
is increased transcriptional activity of STATs.  Our data show increased STAT5 activity in 
response to GH, which is further increased with SOCS2 deficiency.  Overall, these studies 
suggest that SOCS2 expression levels in humans may help determine the efficacy of GH 
therapy in SBS or growth delay.  Responses to GH infusion in SBS patients have been 
variable (207).  We have samples from SBS patients given GH, and future studies will test if 
levels of SOCS2 predict responses to therapy. 
 
E.  Mechanisms of SOCS2 action in intestinal cancer 
 
In Chapter III, SOCS2 deficient mice expressing a GH transgene had increased 
hyperplastic and lymphoid lesions.  These lesion types are generally accepted as benign and 
not pre-cancerous in humans, but their potential to become cancerous in mice is unknown.  
These mice were aged to determine if these colonic polyps could progress to a more pre-
cancerous or cancerous phenotype and to determine if varying SOCS2 levels could further 
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impact on the growth-promoting actions of GH excess over time.  These lesions did not 
progress to a pre-cancerous phenotype, nor did the tumor multiplicity in SOCS2 deficient 
compared to WT mice with GH excess further diverge with aging.  Despite limited sample 
size, one interesting observation was the formation of numerous adenomatous lesions in 
SOCS2+/-/GH-TG mice and an invasive adenocarcinoma in the one generated SOCS2-/-/GH-
TG mouse.  This suggests that during GH excess, reduced levels of SOCS2 promote aberrant 
lesions in intestine.   
To test the potential role of SOCS2 alone in intestinal tumorigenesis, we crossbred 
SOCS2 deficient mice with the ApcMin/+ tumor model.  Our data in Chapter IV shows that 
SOCS2 deficiency increases adenoma in ApcMin/+ mice and are consistent with 
epidemiological data found in humans that SOCS2 silencing by epigenetic hypermethylation 
is linked to various cancer types, including endometrial and ovarian (52, 190).  We used the 
ApcMin/+ mouse model since it is a model of pre-cancerous adenoma, and the protective 
effects we observed of SOCS2 in this model support a role of SOCS2 specifically in early 
adenoma formation.  We also tested if SOCS2 deficiency could increase susceptibility to 
inflammation-associated colon tumors using the AOM/DSS model, since intestinal epithelial-
specific knockout of SOCS3 leads to an increase in inflammation-associated tumorigenesis 
(162).  There was no significant difference in tumors in SOCS2-/- or SOCS2+/+ tumors using 
this model, suggesting that the role of SOCS2 in inflammation-associated neoplasia is 
limited.  
 Future studies in the laboratory will be aimed at determining the mechanism by which 
SOCS2 deficiency leads to increased tumors.  Tumors in the SOCS2/ApcMin/+ and 
GH/SOCS2 models will be assessed for phosphoEGFR, phosphoIGF-IR, and signaling 
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molecules downstream of β-catenin-mediated transcription by immunohistochemistry, 
Western immunoblotting, or quantitative RT-PCR.  An interesting experiment would be to 
crossbreed IRS-1 deficient mice with SOCS2 deficient mice to determine if IRS-1 deficiency 
reverses the increased tumor phenotype in SOCS2 deficient mice, since SOCS2 has been 
shown to inhibit IRS-1 activation (120).  Because IRS-1-/- mice are born at a low frequency 
and breeding would be complicated by a triple-crossbreeding strategy (IRS-1 knockout, 
SOCS2 knockout, and ApcMin/+), such studies might be limited to IRS-1+/- rather than IRS-1-
/-.  IRS-1+/- mice may have sufficient IRS-1 levels for SOCS2 deficiency to promote tumors 
via the IGF/IRS pathway.  Thus, simpler studies could be performed by treating SOCS2-/-
/Min mice with IGF-IR kinase inhibitors like VP-AEW541 or PPP, which are commercially 
available (129, 176).  Ideally, these studies would be performed using a cell-permeant IRS-1 
inhibitor, to most closely mimic the effect in IRS-1-/- mice, however IRS-1 inhibitors have 
not yet been generated.  Since SOCS2 may protect against cancer by inhibiting the EGF 
pathway as well, SOCS2-/- mice could be treated with EGFR inhibitors, such as the 
commercially-available mouse-human chimeric EGFR monoclonal antibody Cetuximab (13), 
to determine if inhibiting this pathway could reverse the effect of disrupting SOCS2 
signaling. 
Increasing evidence suggests that SOCS2 may serve as an endogenous inhibitor of the 
trophic actions of IRS-1 and manipulating SOCS2 levels may serve as a safer and more 
effective mode of cancer prevention therapy than introducing drugs that are not normally 
produced in the body.  Our studies show that SOCS2 deficiency leads to greater 
susceptibility to intestinal tumors, providing further support for its normal role as a tumor 
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suppressor.  Since SOCS2 has been linked to several tumor-promoting signaling pathways, 
including GH, IGF-I, IRS-1, EGF, and STATs, SOCS2 may have greater efficacy in 
preventing or treating colon cancer than one inhibitor alone.  Furthermore, SOCS2 mimetics 
may be useful in combination with other non-specific modes of treatment, such as 
chemotherapy.  The major limitation of chemotherapeutic treatment of cancer are the side-
effects that occur, including nausea, diarrhea, and malabsorption due to the toxic effects on 
the intestinal epithelium.  In combination with SOCS2 mimetics, chemotherapy may be 
effective at lower doses, limiting harmful side effects.  Our laboratory is interested in testing 
cell-permeant SOCS2 mimetics (CP-SOCS2) for prevention or treatment of neoplastic 
growth.  CP-SOCS2 mimetics in cell lines will likely be crucial in determining the pathways 
that SOCS2 modulates, by testing for activated IGF-I, IRS-1, EGF, and STAT transcriptional 
activity.  In the future, we also wish to test the efficacy of CP-SOCS2 in the ApcMin/+ model 
of polyposis. 
 
F.  Relevance of the ApcMin/+ model 
 
We chose the ApcMin/+ model of intestinal polyposis to study the role of IRS-1 and 
SOCS2 in intestinal adenoma since chemical carcinogen-induced intestinal tumors have a 
long latency and low penetrance, and tumor xenografts in nude mice lack the tumor 
microenvironment typical of a tumor that is formed in situ (3).  However, one potential 
caveat of our studies is that the ApcMin/+ mouse model develops polyposis mainly in the small 
intestine, while humans develop APC-mediated polyposis in the colon.  While this difference 
between humans and mice may limit the human relevance of our findings, it is also possible 
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that because the mouse small intestine and human colon are both particularly susceptible to 
β-catenin mediated tumors, the mouse small intestine may have crucial genetic similarities to 
human colon that make it useful for studying colon cancer.  Since this is difficult to test, 
performing additional studies in PIRC (polyposis in the rat colon) rats that get colon tumors 
may be of considerable interest.  PIRC rats have a knockout allele of the Apc gene and mimic 
human colon cancer, showing the ability to progress to invasive adenocarcinoma with age 
and displaying sexual dimorphism, with tumor prevalence moderately higher in males 
compared to females (3).  This rat model could be ideal for longitudinal studies of the effect 
of IRS-1 and SOCS2 inhibitors or mimetics over time, since they have proven useful in 
MicroCT and endoscopy studies (3).   
 
G.  Identifying cancer pathways through tumor microarrays 
 
Microarray studies performed in the Threadgill laboratory at UNC-CH suggest that 
tumors that form in ApcMin/+ mice despite an EGFR inactivation mutation (EGFRwa2) have 
elevated IGFBP5 and IGF-IR expression (communication with Dr. Ming Yu and Dr. David 
Threadgill).  Experiments testing whether tumors that form in ApcMin/+ mice despite 
abrogated IGF system signaling (such as in IRS-1 deficient mice) have enhanced EGF 
signaling will be crucial to determine if IGF-I and EGF signal, at least partially, through 
independent tumor-promoting pathways.  Studies in our laboratory will test whether treating 
IRS-1 deficient mice with the ApcMin/+ mutation with an EGFR inhibitor decreases tumor 
formation to a greater extent than IRS-1 deficiency or EGFR inhibition alone.  If tumors still 
form despite inhibiting both the IRS-1 and EGFR pathways, our lab will perform microarrays 
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on the remaining tumors to identify any novel genes contributing to the tumor phenotype.  
Since SOCS2 may serve as a potent endogenous inhibitor of IGF-I and EGF signaling 
simultaneously, it would be desirable to examine ApcMin/+ mice treated with CP-SOCS2 for 
tumors.  Any tumors arising despite inhibition of pro-tumorigenic pathways by SOCS2 
action could be examined by microarray to help explore how such tumors can “escape” 
inhibition of regulatory pathways and elucidate the pathways in which SOCS2 may be 
uninvolved or only weakly involved. 
 
H.  Biomarkers for colon cancer screening 
 
The current studies have important implications for prevention and treatment of colon 
cancer.  IRS-1 levels may determine susceptibility to colon cancer and could potentially 
serve as a biomarker in screening for genetic factors that increase ones risk of developing the 
disease.  Identifying relative colon cancer susceptibility could help health care professionals 
focus their screening on ‘high risk’ groups, leading to earlier diagnosis and saving on health 
care costs.  By screening for mutations or polymorphisms of genes involved in colon cancer, 
dietary, lifestyle, and screening recommendations could be tailored to an individual’s relative 
risk.   
Our laboratory is involved in the North Carolina colon cancer screening study led by 
Dr. Robert Sandler, in which patients with no prior history of colon cancer undergo routine 
colonoscopy.  Patients are classified as a case if an adenoma was found or as a control if not, 
while patients in which cancer was detected are excluded.  During colonoscopy, normal 
mucosa is biopsied to determine a “field effect” of certain lifestyle or genetic factors in 
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susceptibility to low apoptosis and adenoma formation in cases versus controls and blood is 
collected to assay circulating hormone and lipid profiles.  These studies have already shown 
a significant link between less frequent NSAID use, low levels of apoptosis, high but within 
the normal range of insulin, and high IGFBP3 in adenoma (85, 110).  
A human polymorphism in IRS-1 (G972R) is associated with increased risk of colon 
cancer (187), but the physiological effect of this polymorphism is not known. This 
polymorphism is found in a portion of the IRS-1 coding sequence that is not conserved 
between humans and mice.  Direct test of the effect of this polymorphism would be limited to 
human cell lines, in which one could explore differences in response to IGF-I, proliferation, 
apoptosis, and anchorage-independent growth in cells with and without the polymorphism.  
However, such studies would have to be conducted in human colon cancer cell lines, since 
normal epithelial cell lines are not available.  Future studies in our laboratory will therefore 
determine if the G972R polymorphism in IRS-1 is linked to an increase in local IRS-1 
production in human colon biopsy samples.  We postulate that the G972R IRS-1 
polymorphism leads to increased colon cancer risk by increasing the levels or activity of IRS-
1.  Levels of Sox9 will also be assessed to determine if Sox9 levels in the intestinal mucosa 
are indicative of adenoma susceptibility, since Sox9 levels mimicked IRS-1 status in our 
mouse studies.  In addition, SOCS2 levels in mucosal biopsies will be assessed to determine 
if elevated SOCS2 levels correlate with decreased adenoma development.  We will also 
explore whether SOCS2 silencing by methylation of CpG islands within the SOCS2 
promoter correlates with intestinal adenoma risk in humans undergoing routine colonoscopy.  
These studies are aimed at correlating early pre-cancerous adenoma with SOCS2 methylation 
in patients with no previous history of colon cancer to help determine the molecular 
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mechanisms whereby individuals develop the very earliest stages of intestinal neoplasia. 
  
I.  Summary and working model 
 
 Data provided in this body of work are summarized in our current working model of  
IRS-1 and SOCS2 action in intestinal tumorigenesis, as shown in Figure 5.1.  In our proposed 
working model, IGF-I, IGF-II, and insulin are produced locally in intestine or are released in 
the circulation and act in an endocrine manner by binding the insulin receptor or the IGF-IR.  
IRS-1 lies downstream of all three ligands and docks to the activated receptor and becomes 
phosphorylated.  IRS-1 promotes proliferation and prevents apoptosis of intestinal epithelial 
cells.  Our studies in Chapter II show that the presence of IRS-1 protects against apoptosis of 
potential progenitor/stem cells and promotes intestinal polyposis.  The exact mechanism of 
IRS-1 action remains unknown, although studies described here show that Sox9 levels and 
Sox9 expressing cells are reduced by IRS-1 deficiency, suggesting that Sox9 could be a 
tumor-promoting transcription factor downstream of IRS-1.  Other potential candidates that 
need further exploration are association of IRS-1 with β-catenin and E-cadherin, as well as 
activation of β-catenin transcriptional targets such as Myc and Cyclin D.  SOCS2 has been 
shown to inhibit GH (Chapter III) and IGF-I/IRS-1 (120) action, thereby leading to growth 
inhibition and early differentiation.  SOCS2 deficiency leads to greater tumor number in 
intestine, indicating that SOCS2 normally inhibits tumorigenesis.  In addition to GH and 
IGF/IRS inhibition, SOCS2 may protect against intestinal tumors by inhibiting EGF or STAT 
signaling, both of which have been shown to be major pathways in the pathogenesis of colon 
cancer (18, 115).  A key aim of future studies in the laboratory will be to determine the 
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molecular mechanisms whereby SOCS2 protects against intestinal tumorigenesis.    
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Figure 5.1.  Hypothetical model of IGF/IRS and SOCS2 action in intestinal growth and 
tumorigenesis.  Future directions will be aimed at understanding mechanisms of IRS-1 and 
Sox9 action in normal and aberrant intestinal growth as well as SOCS2 action in 
tumorigenesis. 
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